{ "nodes": [ [ "pomalidomide", "DRUG" ], [ "E3 ubiquitin ligase", "GENE" ], [ "Lenalidomide", "DRUG" ], [ "Neoplasms", "DISEASE" ], [ "Dexamethasone", "DRUG" ], [ "Malignant transformation", "DISEASE" ], [ "Multiple Myeloma", "DISEASE" ], [ "Plasma cell myeloma refractory", "DISEASE" ], [ "Malignant Neoplasms", "DISEASE" ], [ "Diarrhea", "DISEASE" ], [ "Vomiting", "DISEASE" ], [ "Anemia", "DISEASE" ], [ "Thalidomide", "DRUG" ], [ "Relapsed/refractory multiple myeloma", "DISEASE" ], [ "Nausea", "DISEASE" ] ], "edges": [ [ [ "E3 ubiquitin ligase", "Multiple Myeloma" ], 42.275272, [ [ "Kiwamu Hatakeyama, Yoshikane Kikushige, Daisuke Ishihara, Shunsuke Yamamoto, Gentaro Kawano, Taro Tochigi, Toshihiro Miyamoto, Teppei Sakoda, Andy Christoforou, Yuya Kunisaki, Mitsuhiro Fukata, Koji Kato, Takumi Ito, Hiroshi Handa, Koichi Akashi (2024). Thrombospondin-1 is an endogenous substrate of cereblon responsible for immunomodulatory drug-induced thromboembolism. Blood advances, 785-796. https://doi.org/10.1182/bloodadvances.2023010080 PMID: 38163319", "38163319" ], [ "Kai Sun, Lu Yang, Feng Wang, Ying Liu, Nan Xu, Zong-Yan Shi, Wen-Min Chen, Ke Li, Ya-Zhen Qin (2024). PRAME promotes proliferation of multiple myeloma cells through CTMP/Akt/p21/CCND3 axis by ubiquitinating CTMP and p21. Heliyon, e34094. https://doi.org/10.1016/j.heliyon.2024.e34094 PMID: 39071619", "39071619" ], [ "Hojong Yoon, Justine C Rutter, Yen-Der Li, Benjamin L Ebert (2024). Induced protein degradation for therapeutics: past, present, and future. The Journal of clinical investigation. PMID: 38165043", "38165043" ], [ "Paul G Richardson, Suzanne Trudel, Rakesh Popat, María-Victoria Mateos, Annette J Vangsted, Karthik Ramasamy, Joaquín Martinez-Lopez, Hang Quach, Robert Z Orlowski, Mario Arnao, Sagar Lonial, Chatchada Karanes, Charlotte Pawlyn, Kihyun Kim, Albert Oriol, Jesus G Berdeja, Paula Rodríguez Otero, Ignacio Casas-Avilés, Alessia Spirli, Jennifer Poon, Shaoyi Li, Jing Gong, Lilly Wong, Manisha Lamba, Daniel W Pierce, Michael Amatangelo, Teresa Peluso, Paulo Maciag, Jessica Katz, Michael Pourdehnad, Nizar J Bahlis, (2023). Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. The New England journal of medicine, 1009-1022. https://doi.org/10.1056/NEJMoa2303194 PMID: 37646702", "37646702" ], [ "Katherine O Kopp, Margaret E Greer, Elliot J Glotfelty, Shih-Chang Hsueh, David Tweedie, Dong Seok Kim, Marcella Reale, Neil Vargesson, Nigel H Greig (2023). A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders. Biomolecules. https://doi.org/10.3390/biom13050747 PMID: 37238617", "37238617" ], [ "Bert Kwanten, Tine Deconick, Christopher Walker, Feng Wang, Yosef Landesman, Dirk Daelemans (2023). E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 114305. https://doi.org/10.1016/j.biopha.2023.114305 PMID: 36731340", "36731340" ], [ "Mingxing Teng, Wenchao Lu, Katherine A Donovan, Jialin Sun, Noah M Krupnick, Radosław P Nowak, Yen-Der Li, Adam S Sperling, Tinghu Zhang, Benjamin L Ebert, Eric S Fischer, Nathanael S Gray (2022). Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216. Journal of medicinal chemistry, 747-756. https://doi.org/10.1021/acs.jmedchem.1c01832 PMID: 34965125", "34965125" ], [ "Joanna Barankiewicz, Aleksander Salomon-Perzyński, Irena Misiewicz-Krzemińska, Ewa Lech-Marańda (2022). CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma. Cancers. https://doi.org/10.3390/cancers14184492 PMID: 36139651", "36139651" ], [ "Anna Wolska-Washer, Piotr Smolewski (2022). Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies. Cancers. https://doi.org/10.3390/cancers14153778 PMID: 35954440", "35954440" ], [ "Lucia Y Chen, Sarah Gooding (2022). Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma. Frontiers in oncology, 1038329. https://doi.org/10.3389/fonc.2022.1038329 PMID: 36439455", "36439455" ] ] ], [ [ "Lenalidomide", "Anemia" ], 17.425386, [ [ "S Vincent Rajkumar (2024). Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. American journal of hematology, 1802-1824. https://doi.org/10.1002/ajh.27422 PMID: 38943315", "38943315" ], [ "Antonella Bruzzese, Enrica Antonia Martino, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Isabella Capodanno, Antonino Neri, Fortunato Morabito, Ernesto Vigna, Massimo Gentile (2024). Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications. European journal of haematology, 860-869. https://doi.org/10.1111/ejh.14181 PMID: 38294126", "38294126" ], [ "Hyun Kyung Lee, Ha Young Jang, In-Wha Kim, Jung Mi Oh (2024). Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea. Journal of cancer research and clinical oncology, 266. https://doi.org/10.1007/s00432-024-05800-8 PMID: 38769166", "38769166" ], [ "Samuel Yamshon, Gui Zhen Chen, Caitlin Gribbin, Paul Christos, Bijal Shah, Stephen J Schuster, Sonali M Smith, Jakub Svoboda, Richard R Furman, John P Leonard, Peter Martin, Jia Ruan (2023). Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Blood advances, 6579-6588. https://doi.org/10.1182/bloodadvances.2023010606 PMID: 37682791", "37682791" ], [ "Talha Badar, Yazan F Madanat, Amer M Zeidan (2023). Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms. Future oncology (London, England), 1877-1889. https://doi.org/10.2217/fon-2023-0454 PMID: 37750305", "37750305" ], [ "Antonio G Solimando, Markus Krebs, Vanessa Desantis, Donatello Marziliano, Ingrid Catalina Caradonna, Arcangelo Morizio, Antonella Argentiero, Endrit Shahini, Max Bittrich (2023). Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting. Biomedicines. https://doi.org/10.3390/biomedicines11072087 PMID: 37509726", "37509726" ], [ "Chenggong Li, Jia Xu, Wenjing Luo, Danying Liao, Wei Xie, Qiuzhe Wei, Yinqiang Zhang, Xindi Wang, Zhuolin Wu, Yun Kang, Jin'e Zheng, Wei Xiong, Jun Deng, Yu Hu, Heng Mei (2023). Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia. https://doi.org/10.1038/s41375-023-02065-x PMID: 37848634", "37848634" ], [ "Jesus D Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, Kith Pradhan, Mimi Kim, Ioannis Mantzaris, R Alejandro Sica, Nishi Shah, Mendel Goldfinger, Noah Kornblum, Kira Gritsman, Ira Braunschweig, Ulrich Steidl, Britta Will, Aditi Shastri, Amit Verma (2023). Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 60-66. https://doi.org/10.1158/1078-0432.CCR-22-1457 PMID: 36255372", "36255372" ], [ "Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M Ardeshna, Roderick Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam, Luis Fayad, John Radford, Sarah Bailly, Fritz Offner, David Morgan, Javier Munoz, Jerry Ping, Edith Szafer-Glusman, Karl Eckert, Jutta K Neuenburg, Andre Goy (2023). The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study. EClinicalMedicine, 101779. https://doi.org/10.1016/j.eclinm.2022.101779 PMID: 36618900", "36618900" ], [ "Sangeetha Venugopal, Mikkael A Sekeres (2023). Raising the bar for lower-risk myelodysplastic syndromes. Leukemia & lymphoma, 1082-1091. https://doi.org/10.1080/10428194.2023.2197536 PMID: 37029589", "37029589" ] ] ], [ [ "Thalidomide", "Neoplasms" ], 21.088079999999998, [ [ "Gerhard Hamilton, Marie-Therese Eggerstorfer, Sandra Stickler (2024). Development of PROTACS degrading KRAS and SOS1. Oncology research, 1257-1264. https://doi.org/10.32604/or.2024.051653 PMID: 39055890", "39055890" ], [ "Iftekhar Hossain Chowdhury, Shamima Rahman, Yeasmin Jahan Afroze, Sharmeen Tania Shovah (2024). IUPHAR ECR review: Cancer-related anorexia-cachexia in cancer patients: Pathophysiology and treatment. Pharmacological research, 107129. https://doi.org/10.1016/j.phrs.2024.107129 PMID: 38461961", "38461961" ], [ "Deiwakor Chyrmang, Yumkhaibam S Devi, Kishalay Baidya, Laishram J Singh, Daffilyne L Nongrum, Ningthoujam D Devi (2024). A comparative study of whole brain radiotherapy with concomitant thalidomide versus whole brain radiotherapy alone in brain metastases. Journal of cancer research and therapeutics, 255-260. https://doi.org/10.4103/jcrt.jcrt_1724_22 PMID: 38554330", "38554330" ], [ "Esteban Zavaleta-Monestel, Ricardo Quesada-Villaseñor, Monserrat Barrantes-López, Sebastián Arguedas-Chacón, Jeimy Campos-Hernández, Carolina Rojas-Chinchilla, Jonathan García-Montero, Josué Castro-Ulloa, Adriana Anchía-Alfaro, José Ricardo Montenegro-Chaves (2024). Advancements in the Treatment of Multiple Myeloma. Cureus, e74970. https://doi.org/10.7759/cureus.74970 PMID: 39744254", "39744254" ], [ "Tian-Wei Zhang, Peng Zhang, Dong Nie, Xin-Yu Che, Tian-Tai Fu, Yan Zhang (2023). Efficacy of concurrent chemoradiotherapy with thalidomide and S-1 for esophageal carcinoma and its influence on serum tumor markers. World journal of gastrointestinal oncology, 1262-1270. https://doi.org/10.4251/wjgo.v15.i7.1262 PMID: 37546558", "37546558" ], [ "Danilo L Andrade, Mehrsa Jalalizadeh, Ana Clara C Salustiano, Leonardo O Reis (2023). Bladder cancer immunomodulatory effects of intravesical Nitazoxanide, Rapamycin, Thalidomide and Bacillus Calmette-Guérin (BCG). World journal of urology, 2375-2380. https://doi.org/10.1007/s00345-023-04526-5 PMID: 37470811", "37470811" ], [ "Antonio G Solimando, Markus Krebs, Vanessa Desantis, Donatello Marziliano, Ingrid Catalina Caradonna, Arcangelo Morizio, Antonella Argentiero, Endrit Shahini, Max Bittrich (2023). Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting. Biomedicines. https://doi.org/10.3390/biomedicines11072087 PMID: 37509726", "37509726" ], [ "Sylwia Popek-Marciniec, Wojciech Styk, Magdalena Wojcierowska-Litwin, Aneta Szudy-Szczyrek, Paul Dudek, Grazyna Swiderska-Kolacz, Joanna Czerwik-Marcinkowska, Szymon Zmorzynski (2023). The Relationship of CCL5 and CCR1 Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma. Journal of clinical medicine. https://doi.org/10.3390/jcm12062384 PMID: 36983384", "36983384" ], [ "Zohreh Goleh, Manijhe Mokhtari-Dizaji, Tayebeh Toliyat (2022). The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo. Medical oncology (Northwood, London, England), 20. https://doi.org/10.1007/s12032-022-01898-3 PMID: 36434467", "36434467" ], [ "Victor Yu Han Ling, Sreekanth Reddivari, Angel Mary Joseph, Rosie Cox (2022). Oligosecretory myeloma with gastrointestinal tract involvement: an unusual presentation and literature review. BMJ case reports. https://doi.org/10.1136/bcr-2021-247742 PMID: 35365468", "35365468" ] ] ], [ [ "Dexamethasone", "Malignant Neoplasms" ], 19.602768, [ [ "Hashan Pathiraja, Gayathri de Abrew, Linushika de Silva, Sanjaya Fernando, Shobhavi Randeny, Sachith Mettananda (2024). Methotrexate-induced leukoencephalopathy presenting as acute-onset limb weakness in a child: a case report. Journal of medical case reports, 475. https://doi.org/10.1186/s13256-024-04824-5 PMID: 39334488", "39334488" ], [ "Matteo Mario Carlà, Carlos Mateo (2024). Rapidly progressive central retinal pigmented epithelium atrophy after Ivospemin (SBP-101) treatment for pancreatic adenocarcinoma. American journal of ophthalmology case reports, 102200. https://doi.org/10.1016/j.ajoc.2024.102200 PMID: 39502458", "39502458" ], [ "Chayanee Samdaengpan, Prakongboon Sungkasubun, Worawit Chaiwiriyawong, Archara Supavavej, Jomtana Siripaibun, Chumut Phanthunane, Walaipan Tantiyavarong, Wisut Lamlertthon, Teerapat Ungtrakul, Kriangkrai Tawinprai, Kamonwan Soonklang, Thitapha Thongchai, Piyarat Limpawittayakul (2024). Effect of Corticosteroid on Immunogenicity of SARS-CoV-2 Vaccines in Patients With Solid Cancer. JCO global oncology, e2300458. https://doi.org/10.1200/GO.23.00458 PMID: 38781552", "38781552" ], [ "Sabrina Dixon, Arpita Deb, Todd Archer, Barbara L F Kaplan (2024). Potential to use cannabinoids as adjunct therapy for dexamethasone: An in vitro study with canine peripheral blood mononuclear cells. Veterinary immunology and immunopathology, 110727. https://doi.org/10.1016/j.vetimm.2024.110727 PMID: 38330886", "38330886" ], [ "Bishara Jahshan, Anna B Owczarczyk, Hamed Daw, Abdo Haddad (2024). A Case of Secondary Hemophagocytic Lymphohistiocytosis in a Patient With T-cell Lymphoma. Cureus, e56558. https://doi.org/10.7759/cureus.56558 PMID: 38646290", "38646290" ], [ "Duobing Zou, Mei Lv, Ying Chen, Tingting Niu, Chao Ma, Cong Shi, Zhenya Huang, Ying Wu, Shujun Yang, Yun Wang, Ningning Wu, Yi Zhang, Guifang Ouyang, Qitian Mu (2023). Down-regulation of Musashi-2 exerts antileukemic effects on acute lymphoblastic leukemia cells and increases sensitivity to dexamethasone. Annals of hematology. https://doi.org/10.1007/s00277-023-05468-z PMID: 37749318", "37749318" ], [ "Michelle Walter, Eric Hansen, Showkat Hamid, Desi Carozza, Gary Mann, Charles Roche, Anthony George, Kristopher Attwood, Amy Case (2023). Palliative Management of Inoperable Malignant Bowel Obstruction: Prospective, Open Label, Phase 2 Study at an NCI Comprehensive Cancer Center. Journal of pain and symptom management. https://doi.org/10.1016/j.jpainsymman.2023.09.014 PMID: 37769820", "37769820" ], [ "Md Yousuf, Kathyayani Sridharan, Tanushree Mishra, Namita S Mahadik, Rajkumar Banerjee, Susanta S Adhikari (2023). Cationic lipid-conjugated bis-arylidene oxindole derivatives as broad-spectrum breast cancer-selective therapeutics. Bioorganic chemistry, 106395. https://doi.org/10.1016/j.bioorg.2023.106395 PMID: 36753964", "36753964" ], [ "Amy W An, Xi Chen, Diana L Urbauer, Eduardo Bruera, David Hui (2023). Impact of Dosing and Duration of Dexamethasone on Serious Corticosteroid-Related Adverse Events. Journal of pain and symptom management. https://doi.org/10.1016/j.jpainsymman.2023.09.021 PMID: 37769822", "37769822" ], [ "Hadi Abou-El-Hassan, Melvin Kantono, Ankur Bhagat, Janie Hu, David Karp, Renard Jerome, Johnny S Randhawa, Drake Shafer, Farbod Farmand (2023). Hemophagocytic Lymphohistiocytosis Caused by a Severe Epstein-Barr Virus Infection in a Young Patient Presenting With Hiccups. Cureus, e36199. https://doi.org/10.7759/cureus.36199 PMID: 37065339", "37065339" ] ] ], [ [ "Thalidomide", "Anemia" ], 11.783389999999999, [ [ "Kun Yang, Xiaodong Liu, Wei Peng, Fang Hua, Lan Li, Kun Chen, Jin Zhang, Shan Luo, Wanting Li, Yuxi Ding, Jie Chen, Jian Xiao (2024). Effects of Thalidomide on Erythropoiesis and Iron Homeostasis in Transfusion-Dependent β-Thalassemia. Mediterranean journal of hematology and infectious diseases, e2024001. https://doi.org/10.4084/MJHID.2024.001 PMID: 38223482", "38223482" ], [ "Xiang-Mei Yao, Zhi-Xiang Lu, Jian-Hua Rao, Xiao-Li Gao, Qi Wang, Hai-Tao He (2024). [Efficacy and Safety of Ixazomib Combined with Thalidomide and Dexamethasone in Treatment of Multiple Myeloma]. Zhongguo shi yan xue ye xue za zhi, 1450-1454. https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.05.023 PMID: 39479831", "39479831" ], [ "Valeria Maria Pinto, Nicola Romano, Manuela Balocco, Paola Carrara, Martina Lamagna, Sabrina Quintino, Antonio Castaldi, Gian Luca Forni (2024). Reduction of extramedullary erythropoiesis and amelioration of anemia in a β-thalassemia patient treated with thalidomide. American journal of hematology, 463-464. https://doi.org/10.1002/ajh.27189 PMID: 38146593", "38146593" ], [ "Antonio G Solimando, Markus Krebs, Vanessa Desantis, Donatello Marziliano, Ingrid Catalina Caradonna, Arcangelo Morizio, Antonella Argentiero, Endrit Shahini, Max Bittrich (2023). Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting. Biomedicines. https://doi.org/10.3390/biomedicines11072087 PMID: 37509726", "37509726" ], [ "Qi Zhang, Ting Deng, Fen Yang, Weijian Guo, Dan Liu, Jiajia Yuan, Changsong Qi, Yanshuo Cao, Qiuqiong Yu, Huiming Cai, Zhi Peng, Xicheng Wang, Jun Zhou, Ming Lu, Jifang Gong, Jian Li, Yi Ba, Lin Shen (2022). A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor. Frontiers in pharmacology, 833583. https://doi.org/10.3389/fphar.2022.833583 PMID: 35935841", "35935841" ], [ "Farah Qasem, A'sem Abu-Qamar, Batool Aqel, Rand Aladayleh, Alteerah R Ilham, Ahmad Magableh, Hisham Bawa Neh, Feras Al-Fararjeh, Abdalla Awidi (2022). Real World Multiple Myeloma Registry from Jordan, a Developing Country. Mediterranean journal of hematology and infectious diseases, e2022031. https://doi.org/10.4084/MJHID.2022.031 PMID: 35615319", "35615319" ], [ "Antonella Bruzzese, Daniele Derudas, Monica Galli, Enrica Antonia Martino, Stefano Rocco, Concetta Conticello, Catello Califano, Nicola Giuliani, Silvia Mangiacavalli, Giuliana Farina, Alessandra Lombardo, Marino Brunori, Elena Rossi, Elisabetta Antonioli, Roberto Ria, Renato Zambello, Nicola Di Renzo, Giuseppe Mele, Gianpaolo Marcacci, Giuseppe Pietrantuono, Gaetano Palumbo, Nicola Cascavilla, Claudio Cerchione, Angelo Belotti, Clelia Criscuolo, Giuseppina Uccello, Paola Curci, Ernesto Vigna, Francesco Mendicino, Enrico Iaccino, Selena Mimmi, Cirino Botta, Donatella Vincelli, Nicola Sgherza, Angela Bonalumi, Luca Cupelli, Raffaella Stocchi, Massimo Martino, Stelvio Ballanti, Dominella Gangemi, Alfredo Gagliardi, Barbara Gamberi, Alessandra Pompa, Giovanni Tripepi, Ferdinando Frigeri, Ugo Consoli, Sara Bringhen, Elena Zamagni, Francesca Patriarca, Valerio De Stefano, Francesco Di Raimondo, Salvatore Palmieri, Maria Teresa Petrucci, Massimo Offidani, Pellegrino Musto, Mario Boccadoro, Michele Cavo, Antonino Neri, Fortunato Morabito, Massimo Gentile (2022). Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. Hematological oncology, 704-715. https://doi.org/10.1002/hon.3031 PMID: 35608183", "35608183" ], [ "Shiqiang Qu, Zefeng Xu, Tiejun Qin, Bing Li, Lijuan Pan, Jia Chen, Xin Yan, Junying Wu, Yudi Zhang, Peihong Zhang, Robert Peter Gale, Zhijian Xiao (2022). Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study. Hematological oncology, 787-795. https://doi.org/10.1002/hon.3026 PMID: 35609279", "35609279" ], [ "Saman Hewamana, Prasanna Gunasena, Chathuri Jayasinghe, Thurairajah Skandarajah, Mahesh Harischandra, Sobitha Abeyaratne, Lalith Ekanayake, Gnani Somasundaram, Surjit Somiah, Vadivelu Srinivasan, Gehan Arseculeratne, Neomal Perera, Jayaindra Fernando, Mazhar Faiz, Nihal Munasinghe, Ashfaq Mowlana, Samadhi Deshapriya, Supun Mawathakubura, Chandana Wickramarathna, Ananda Wijewickrama, Priyankara Jayawardena, Eranga Perera, Natasha Peiris, Sarath Paranawithane, Chitranganie Perera, Chitranga Kariyawasam, Sanjeewa Munasinghe, Chandu De Silva, Rohini Wadanamby, Geethani Galagoda, Thet Thet Lin, Bandula Wijesiriwardena, Jayantha Balawardena (2022). Response and Survival Estimates of Patients With Plasma Cell Myeloma in a Resource-Constrained Setting Using Protocols From High-Income Countries: A Single-Center Experience From Sri Lanka. JCO global oncology, e2100352. https://doi.org/10.1200/GO.21.00352 PMID: 35772042", "35772042" ], [ "Viera Sandecká, Luděk Pour, Ivan Špička, Jiří Minařík, Jakub Radocha, Tomáš Jelínek, Adriana Heindorfer, Petr Pavlíček, Michal Sýkora, Alexandra Jungová, Petr Kessler, Marek Wróbel, David Starostka, Jana Ullrychová, Lukáš Stejskal, Martin Štork, Jan Straub, Tomáš Pika, Lucie Brožová, Sabina Ševčíková, Vladimír Maisnar, Roman Hájek (2021). Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. European journal of haematology, 466-474. https://doi.org/10.1111/ejh.13683 PMID: 34272773", "34272773" ] ] ], [ [ "E3 ubiquitin ligase", "pomalidomide" ], 14.104322000000002, [ [ "Shiwei Liu, Qingpeng Lv, Xinyu Mao, Hui Dong, Wenjing Xu, Xuanlong Du, Weilu Jia, Kun Feng, Jiaqi Zhang, Yewei Zhang (2024). O-GlcNAcylated RALY Contributes to Hepatocellular Carcinoma Cells Proliferation by Regulating USP22 mRNA Nuclear Export. International journal of biological sciences, 3675-3690. https://doi.org/10.7150/ijbs.97397 PMID: 38993567", "38993567" ], [ "Shiwei Liu, Fukang Yuan, Hui Dong, Jiaqi Zhang, Xinyu Mao, Yangsui Liu, Huansong Li (2024). PTGES3 proteolysis using the liposomal peptide-PROTAC approach. Biology direct, 144. https://doi.org/10.1186/s13062-024-00580-0 PMID: 39726032", "39726032" ], [ "Paul G Richardson, Suzanne Trudel, Rakesh Popat, María-Victoria Mateos, Annette J Vangsted, Karthik Ramasamy, Joaquín Martinez-Lopez, Hang Quach, Robert Z Orlowski, Mario Arnao, Sagar Lonial, Chatchada Karanes, Charlotte Pawlyn, Kihyun Kim, Albert Oriol, Jesus G Berdeja, Paula Rodríguez Otero, Ignacio Casas-Avilés, Alessia Spirli, Jennifer Poon, Shaoyi Li, Jing Gong, Lilly Wong, Manisha Lamba, Daniel W Pierce, Michael Amatangelo, Teresa Peluso, Paulo Maciag, Jessica Katz, Michael Pourdehnad, Nizar J Bahlis, (2023). Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. The New England journal of medicine, 1009-1022. https://doi.org/10.1056/NEJMoa2303194 PMID: 37646702", "37646702" ], [ "Haibo Xie, Chunrong Li, Hua Tang, Ira Tandon, Junzhuo Liao, Brett L Roberts, Yu Zhao, Weiping Tang (2023). Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation. Journal of medicinal chemistry, 2904-2917. https://doi.org/10.1021/acs.jmedchem.2c01941 PMID: 36749666", "36749666" ], [ "Katherine O Kopp, Margaret E Greer, Elliot J Glotfelty, Shih-Chang Hsueh, David Tweedie, Dong Seok Kim, Marcella Reale, Neil Vargesson, Nigel H Greig (2023). A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders. Biomolecules. https://doi.org/10.3390/biom13050747 PMID: 37238617", "37238617" ], [ "Po-Chang Shih, Miyako Naganuma, Genichiro Tsuji, Yosuke Demizu, Mikihiko Naito (2023). Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3. Bioorganic & medicinal chemistry, 117507. https://doi.org/10.1016/j.bmc.2023.117507 PMID: 37922656", "37922656" ], [ "Hamidreza Sohbati, Mohsen Amini, Saeed Balalaie (2022). Synthesis and Biological Evaluation of Novel Anti-leukemia Proteolysis-Targeting Chimeras in Degradating Inosine Monophosphate Dehydrogenase. Iranian journal of pharmaceutical research : IJPR, e129251. https://doi.org/10.5812/ijpr-129251 PMID: 36942064", "36942064" ], [ "Kun Wang, Xiaoyong Dai, Albert Yu, Chunyan Feng, Kewei Liu, Laiqiang Huang (2022). Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression. Journal of experimental & clinical cancer research : CR, 289. https://doi.org/10.1186/s13046-022-02483-2 PMID: 36171633", "36171633" ], [ "Hanqiao Xu, Takashi Kurohara, Reina Takano, Hidetomo Yokoo, Norihito Shibata, Nobumichi Ohoka, Takao Inoue, Mikihiko Naito, Yosuke Demizu (2022). Development of Rapid and Facile Solid-Phase Synthesis of PROTACs via a Variety of Binding Styles. ChemistryOpen, e202200131. https://doi.org/10.1002/open.202200131 PMID: 35822913", "35822913" ], [ "Hao Guo, Jingyi Yang, Haoran Wang, Xingchen Liu, Yanyan Liu, Keshu Zhou (2022). Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. Frontiers in immunology, 1017990. https://doi.org/10.3389/fimmu.2022.1017990 PMID: 36311747", "36311747" ] ] ], [ [ "Dexamethasone", "Nausea" ], 14.939596, [ [ "Satoko Arai, Saki Oida, Akio Murakami, Keiichi Koido, Nobuhisa Teranishi, Takahiro Gunji (2024). [Effects of Dexamethasone Reduction on Chemotherapy Prophylactic Antiemetic Therapy for Gastrointestinal Cancer under Dexamethasone Supply Difficulties during COVID-19]. Gan to kagaku ryoho. Cancer & chemotherapy, 1029-1032. PMID: 39571988", "39571988" ], [ "Nanjin Chen, Shuman Ji, Junfei Liu, Liping Wang, Fenglin Chen, Yanwu Zhu, Jiao Li, Minjuan Chen, Lingyang Chen, Mingcang Wang, Ruyi He, Xiaopeng Mei, Zhanqin Zhang, Shengwei Jin, Jingming Zheng, Yongpo Jiang (2024). Olanzapine for the prevention of postoperative nausea and vomiting after gynecologic laparoscopic surgery: a randomized controlled trial. Therapeutic advances in drug safety, 20420986241244593. https://doi.org/10.1177/20420986241244593 PMID: 38646425", "38646425" ], [ "Hitomi Sakai, Junji Tsurutani, Yukinori Ozaki, Hiroshi Ishiguro, Kazuki Nozawa, Kenichi Watanabe, Shigeto Maeda, Takamichi Yokoe, Chiyo K Imamura, Koji Matsumoto, Tsutomu Iwasa, Yasutaka Chiba, Daisuke Takiguchi, Toshimi Takano (2023). Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B). BMJ open, e070304. https://doi.org/10.1136/bmjopen-2022-070304 PMID: 37012013", "37012013" ], [ "Michelle Walter, Eric Hansen, Showkat Hamid, Desi Carozza, Gary Mann, Charles Roche, Anthony George, Kristopher Attwood, Amy Case (2023). Palliative Management of Inoperable Malignant Bowel Obstruction: Prospective, Open Label, Phase 2 Study at an NCI Comprehensive Cancer Center. Journal of pain and symptom management. https://doi.org/10.1016/j.jpainsymman.2023.09.014 PMID: 37769820", "37769820" ], [ "Xi Chen, Wenxing Liu, Xiaohua Guo, Lifeng Zhou, Wenlong Liu (2023). Dexamethasone Decreased Postoperative Complications in Tonsillotomy. Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses. https://doi.org/10.1016/j.jopan.2023.06.093 PMID: 37855764", "37855764" ], [ "Bin Wu, Ling Zeng, Kaifa Peng, Xi Shao, Li Liu, Rongyong Man, Xianbi Tang, Yushi Zhong (2023). Radiological findings of contrast-induced encephalopathy following cerebral angiography: A case report. Medicine, e33855. https://doi.org/10.1097/MD.0000000000033855 PMID: 37335699", "37335699" ], [ "Shunsuke Okuyama, Masayuki Ueno, Takahisa Kayahara, Hiroyuki Takabatake, Yoichi Morimoto, Motowo Mizuno (2022). [Antiemetic Therapy for Vomiting and Nausea Related to Hepatic Arterial Infusion Chemotherapy Using Cisplatin in Patients with Hepatocellular Carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 951-955. PMID: 36156013", "36156013" ], [ "Tomás B Corcoran, Catherine Martin, Edmond O'Loughlin, Kwok M Ho, Pauline Coutts, Matthew T Chan, Andrew Forbes, Kate Leslie, Paul Myles (2022). Dexamethasone and clinically significant postoperative nausea and vomiting: a prespecified substudy of the randomised perioperative administration of dexamethasone and infection (PADDI) trial. British journal of anaesthesia, 327-335. https://doi.org/10.1016/j.bja.2022.05.018 PMID: 35803757", "35803757" ], [ "Abdolah Razi, Esmaeil Farrokhi, Pegah Lotfabadi, Somayeh Sadat Hosseini, Hassan Saadati, Ramin Haghighi, Maryam Rameshrad (2022). Dexamethasone and ketorolac compare with ketorolac alone in acute renal colic: A randomized clinical trial. The American journal of emergency medicine, 245-250. https://doi.org/10.1016/j.ajem.2022.05.054 PMID: 35738193", "35738193" ], [ "Liangku Huang, Peng Li, Liang Zhang, Guangming Kang, Haizhen Zhou, Zandong Zhao (2022). Analgesic comparison between perineural and intravenous dexamethasone for shoulder arthroscopy: a meta-analysis of randomized controlled trials. Journal of orthopaedic surgery and research, 103. https://doi.org/10.1186/s13018-022-02952-6 PMID: 35177116", "35177116" ] ] ], [ [ "Dexamethasone", "Vomiting" ], 13.956352, [ [ "Satoko Arai, Saki Oida, Akio Murakami, Keiichi Koido, Nobuhisa Teranishi, Takahiro Gunji (2024). [Effects of Dexamethasone Reduction on Chemotherapy Prophylactic Antiemetic Therapy for Gastrointestinal Cancer under Dexamethasone Supply Difficulties during COVID-19]. Gan to kagaku ryoho. Cancer & chemotherapy, 1029-1032. PMID: 39571988", "39571988" ], [ "Baona Wang, Huaqing Chu, Shijing Wei, Huan Hsu, Jiao Geng, Mengyuan Xu, Xin Zhang, Jie Yu, Hui Zheng (2024). Exploration of treatment strategies and susceptibility gene of postoperative nausea and vomiting in breast cancer patients: a randomised controlled trial. Breast cancer (Tokyo, Japan), 926-934. https://doi.org/10.1007/s12282-024-01606-1 PMID: 38896170", "38896170" ], [ "Hitomi Sakai, Junji Tsurutani, Yukinori Ozaki, Hiroshi Ishiguro, Kazuki Nozawa, Kenichi Watanabe, Shigeto Maeda, Takamichi Yokoe, Chiyo K Imamura, Koji Matsumoto, Tsutomu Iwasa, Yasutaka Chiba, Daisuke Takiguchi, Toshimi Takano (2023). Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B). BMJ open, e070304. https://doi.org/10.1136/bmjopen-2022-070304 PMID: 37012013", "37012013" ], [ "Xi Chen, Wenxing Liu, Xiaohua Guo, Lifeng Zhou, Wenlong Liu (2023). Dexamethasone Decreased Postoperative Complications in Tonsillotomy. Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses. https://doi.org/10.1016/j.jopan.2023.06.093 PMID: 37855764", "37855764" ], [ "Do Hyun Kim, Sung Won Kim, Mohammed Abdullah Basurrah, Se Hwan Hwang (2023). The efficacy and safety of peri-tonsillar administrated agents on pain treatment after pediatric tonsillectomy: A network meta-analysis. International journal of pediatric otorhinolaryngology, 111455. https://doi.org/10.1016/j.ijporl.2023.111455 PMID: 36696709", "36696709" ], [ "Bin Wu, Ling Zeng, Kaifa Peng, Xi Shao, Li Liu, Rongyong Man, Xianbi Tang, Yushi Zhong (2023). Radiological findings of contrast-induced encephalopathy following cerebral angiography: A case report. Medicine, e33855. https://doi.org/10.1097/MD.0000000000033855 PMID: 37335699", "37335699" ], [ "Shunsuke Okuyama, Masayuki Ueno, Takahisa Kayahara, Hiroyuki Takabatake, Yoichi Morimoto, Motowo Mizuno (2022). [Antiemetic Therapy for Vomiting and Nausea Related to Hepatic Arterial Infusion Chemotherapy Using Cisplatin in Patients with Hepatocellular Carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 951-955. PMID: 36156013", "36156013" ], [ "Tomás B Corcoran, Catherine Martin, Edmond O'Loughlin, Kwok M Ho, Pauline Coutts, Matthew T Chan, Andrew Forbes, Kate Leslie, Paul Myles (2022). Dexamethasone and clinically significant postoperative nausea and vomiting: a prespecified substudy of the randomised perioperative administration of dexamethasone and infection (PADDI) trial. British journal of anaesthesia, 327-335. https://doi.org/10.1016/j.bja.2022.05.018 PMID: 35803757", "35803757" ], [ "Andhika Putra, Michaela Austel, Frane Banovic (2022). A retrospective evaluation of the steroid sparing effects of oral mycophenolate mofetil (MMF) as an adjunct immunosuppressant for the treatment of canine pemphigus foliaceus. Veterinary dermatology, 77-e24. https://doi.org/10.1111/vde.13028 PMID: 34697841", "34697841" ], [ "Abdolah Razi, Esmaeil Farrokhi, Pegah Lotfabadi, Somayeh Sadat Hosseini, Hassan Saadati, Ramin Haghighi, Maryam Rameshrad (2022). Dexamethasone and ketorolac compare with ketorolac alone in acute renal colic: A randomized clinical trial. The American journal of emergency medicine, 245-250. https://doi.org/10.1016/j.ajem.2022.05.054 PMID: 35738193", "35738193" ] ] ], [ [ "Thalidomide", "Multiple Myeloma" ], 59.105214000000004, [ [ "Nader Slama, Inaam Bizid, Ahlem Bellalah, Mabrouk Abdelali, Mohamed Adnene Laatiri (2024). Extramedullary plasmacytoma of the orbit complicating the evolution of multiple myeloma in complete remission. Leukemia research reports, 100460. https://doi.org/10.1016/j.lrr.2024.100460 PMID: 38707773", "38707773" ], [ "Alejandro Meraz-Munoz, Hira Mian, David Kirkwood, Nivethika Jeyakumar, Arleigh McCurdy, Navdeep Tangri, Refik Saskin, Nelson Leung, Ron Wald, Abhijat Kitchlu (2024). Pomalidomide Use and Kidney Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study. Clinical lymphoma, myeloma & leukemia, e861-e869. https://doi.org/10.1016/j.clml.2024.07.007 PMID: 39117532", "39117532" ], [ "Bin Wang, Wanting Qiang, Jia Yi, Shouhong Gao, Bosu Meng, Yuhui Mu, Bolong Wang, Zhipeng Wang, Xia Tao (2023). Simultaneous quantification of thalidomide, lenalidomide and pomadomide in plasma by LC-MS/MS. Journal of pharmacological and toxicological methods, 107250. https://doi.org/10.1016/j.vascn.2023.107250 PMID: 36627002", "36627002" ], [ "Yuka Kawahara, Saeko Murata, Tadashi Shimizu, Yoshihiro Uesawa, Mayako Uchida (2023). Assessment of Time-to-onset and Outcome of Lung Adverse Events With Pomalidomide from a Pharmacovigilance Study. In vivo (Athens, Greece), 955-961. https://doi.org/10.21873/invivo.13168 PMID: 36881059", "36881059" ], [ "Karthik Ramasamy, Gulnaz Iqbal, Richard Brouwer, Victoria Stalker, Salma Akhtar, Sherin Varghese, Jindriska Lindsay, Stephen Schey, Mark Drayson, Janet Dunn (2022). Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial. Blood cancer journal, 162. https://doi.org/10.1038/s41408-022-00758-7 PMID: 36446771", "36446771" ], [ "Victor Yu Han Ling, Sreekanth Reddivari, Angel Mary Joseph, Rosie Cox (2022). Oligosecretory myeloma with gastrointestinal tract involvement: an unusual presentation and literature review. BMJ case reports. https://doi.org/10.1136/bcr-2021-247742 PMID: 35365468", "35365468" ], [ "Holger W Auner, Sarah R Brown, Katrina Walker, Jessica Kendall, Bryony Dawkins, David Meads, Gareth J Morgan, Martin F Kaiser, Mark Cook, Sadie Roberts, Christopher Parrish, Gordon Cook (2022). Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. Blood cancer journal, 52. https://doi.org/10.1038/s41408-022-00626-4 PMID: 35365598", "35365598" ], [ "Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C Béné, Sonja Zweegman, Hélène Caillon, Denis Caillot, Jill Corre, Michel Delforge, Thomas Dejoie, Chantal Doyen, Thierry Facon, Cécile Sonntag, Jean Fontan, Mohamad Mohty, Kon-Siong Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Margaret Macro, Frédérique Orsini-Piocelle, Murielle Roussel, Anne-Marie Stoppa, Niels W C J van de Donk, Soraya Wuillème, Annemiek Broijl, Cyrille Touzeau, Mourad Tiab, Jean-Pierre Marolleau, Nathalie Meuleman, Marie-Christiane Vekemans, Matthijs Westerman, Saskia K Klein, Mark-David Levin, Fritz Offner, Martine Escoffre-Barbe, Jean-Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Maria Krevvata, Ke Zhang, Carla de Boer, Sanjay Vara, Tobias Kampfenkel, Veronique Vanquickelberghe, Jessica Vermeulen, Hervé Avet-Loiseau, Pieter Sonneveld (2021). Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. The Lancet. Oncology, 1378-1390. https://doi.org/10.1016/S1470-2045(21)00428-9 PMID: 34529931", "34529931" ], [ "Kevin R Kelly, Sikander Ailawadhi, David S Siegel, Leonard T Heffner, George Somlo, Sundar Jagannath, Todd M Zimmerman, Nikhil C Munshi, Sumit Madan, Asher Chanan-Khan, Sagar Lonial, Suraj Chandwani, Ashot Minasyan, Markus Ruehle, Farima Barmaki-Rad, Afsaneh Abdolzade-Bavil, Faiza Rharbaoui, Eva Herrmann-Keiner, Thomas Haeder, Andrea Wartenberg-Demand, Kenneth C Anderson (2021). Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. The Lancet. Haematology, e794-e807. https://doi.org/10.1016/S2352-3026(21)00208-8 PMID: 34529955", "34529955" ], [ "Chih-Ning Cheng, Shang-Yi Huang, Pei-Wen Lien, Shih-Ting Huang, Fang-Ju Lin (2021). Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan. PloS one, e0252124. https://doi.org/10.1371/journal.pone.0252124 PMID: 34038463", "34038463" ] ] ], [ [ "E3 ubiquitin ligase", "Thalidomide" ], 42.286339999999996, [ [ "Shiwei Liu, Fukang Yuan, Hui Dong, Jiaqi Zhang, Xinyu Mao, Yangsui Liu, Huansong Li (2024). PTGES3 proteolysis using the liposomal peptide-PROTAC approach. Biology direct, 144. https://doi.org/10.1186/s13062-024-00580-0 PMID: 39726032", "39726032" ], [ "Gerhard Hamilton, Marie-Therese Eggerstorfer, Sandra Stickler (2024). Development of PROTACS degrading KRAS and SOS1. Oncology research, 1257-1264. https://doi.org/10.32604/or.2024.051653 PMID: 39055890", "39055890" ], [ "Jeremy Hall, Zhuoran Zhang, Supriyo Bhattacharya, Dongfang Wang, Marice Alcantara, Yong Liang, Piotr Swiderski, Stephen Forman, Larry Kwak, Nagarajan Vaidehi, Marcin Kortylewski (2024). Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3. Molecular therapy. Nucleic acids, 102137. https://doi.org/10.1016/j.omtn.2024.102137 PMID: 38384444", "38384444" ], [ "Hojong Yoon, Justine C Rutter, Yen-Der Li, Benjamin L Ebert (2024). Induced protein degradation for therapeutics: past, present, and future. The Journal of clinical investigation. PMID: 38165043", "38165043" ], [ "Marcin Cieślak, Marta Słowianek (2023). Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges? Pharmaceutics. https://doi.org/10.3390/pharmaceutics15030812 PMID: 36986673", "36986673" ], [ "Radosław P Nowak, Jianwei Che, Silas Ferrao, Nikki R Kong, Hu Liu, Breanna L Zerfas, Lyn H Jones (2023). Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives. RSC medicinal chemistry, 501-506. https://doi.org/10.1039/d2md00347c PMID: 36970148", "36970148" ], [ "Jian Yan, Zhibing Zheng (2023). Discovery of Highly Potent CRBN Ligands and Insight into Their Binding Mode through Molecular Docking and Molecular Dynamics Simulations. ChemMedChem, e202200573. https://doi.org/10.1002/cmdc.202200573 PMID: 36750890", "36750890" ], [ "Ota Fuchs (2023). Targeting cereblon in hematologic malignancies. Blood reviews, 100994. https://doi.org/10.1016/j.blre.2022.100994 PMID: 35933246", "35933246" ], [ "Po-Chang Shih, Miyako Naganuma, Genichiro Tsuji, Yosuke Demizu, Mikihiko Naito (2023). Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3. Bioorganic & medicinal chemistry, 117507. https://doi.org/10.1016/j.bmc.2023.117507 PMID: 37922656", "37922656" ], [ "Andrea G Shergalis, Violeta L Marin, David Y Rhee, Sameera Senaweera, Rebecca L McCloud, Judith A Ronau, Charles W Hutchins, Shaun McLoughlin, Kevin R Woller, Scott E Warder, Anil Vasudevan, Justin M Reitsma (2023). CRISPR Screen Reveals BRD2/4 Molecular Glue-like Degrader via Recruitment of DCAF16. ACS chemical biology, 331-339. https://doi.org/10.1021/acschembio.2c00747 PMID: 36656921", "36656921" ] ] ], [ [ "E3 ubiquitin ligase", "Lenalidomide" ], 56.336104999999996, [ [ "Hojong Yoon, Justine C Rutter, Yen-Der Li, Benjamin L Ebert (2024). Induced protein degradation for therapeutics: past, present, and future. The Journal of clinical investigation. PMID: 38165043", "38165043" ], [ "Linyao Fan, Yingqiu Qi, Xi Yang, Yarui Xu, Yana Zhang, Longdi Wang, Anying Zhu, Lirong Zhang, Jian Song, Shengnan Du, Guangjun Nie, Huan Min (2024). Targeted degradation of LRG1 to attenuate renal fibrosis. Asian journal of pharmaceutical sciences, 100941. https://doi.org/10.1016/j.ajps.2024.100941 PMID: 39246511", "39246511" ], [ "Jian Yan, Zhibing Zheng (2023). Discovery of Highly Potent CRBN Ligands and Insight into Their Binding Mode through Molecular Docking and Molecular Dynamics Simulations. ChemMedChem, e202200573. https://doi.org/10.1002/cmdc.202200573 PMID: 36750890", "36750890" ], [ "Paul G Richardson, Suzanne Trudel, Rakesh Popat, María-Victoria Mateos, Annette J Vangsted, Karthik Ramasamy, Joaquín Martinez-Lopez, Hang Quach, Robert Z Orlowski, Mario Arnao, Sagar Lonial, Chatchada Karanes, Charlotte Pawlyn, Kihyun Kim, Albert Oriol, Jesus G Berdeja, Paula Rodríguez Otero, Ignacio Casas-Avilés, Alessia Spirli, Jennifer Poon, Shaoyi Li, Jing Gong, Lilly Wong, Manisha Lamba, Daniel W Pierce, Michael Amatangelo, Teresa Peluso, Paulo Maciag, Jessica Katz, Michael Pourdehnad, Nizar J Bahlis, (2023). Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. The New England journal of medicine, 1009-1022. https://doi.org/10.1056/NEJMoa2303194 PMID: 37646702", "37646702" ], [ "Haibo Xie, Chunrong Li, Hua Tang, Ira Tandon, Junzhuo Liao, Brett L Roberts, Yu Zhao, Weiping Tang (2023). Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation. Journal of medicinal chemistry, 2904-2917. https://doi.org/10.1021/acs.jmedchem.2c01941 PMID: 36749666", "36749666" ], [ "Katherine O Kopp, Margaret E Greer, Elliot J Glotfelty, Shih-Chang Hsueh, David Tweedie, Dong Seok Kim, Marcella Reale, Neil Vargesson, Nigel H Greig (2023). A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders. Biomolecules. https://doi.org/10.3390/biom13050747 PMID: 37238617", "37238617" ], [ "Geoffrey P Dann, Hu Liu, Radosław P Nowak, Lyn H Jones (2023). Cereblon target validation using a covalent inhibitor of neosubstrate recruitment. Methods in enzymology, 155-167. https://doi.org/10.1016/bs.mie.2022.08.056 PMID: 36764755", "36764755" ], [ "Takumi Ito (2022). [Development of novel cereblon modulators and their target molecules]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 573-579. https://doi.org/10.11406/rinketsu.63.573 PMID: 35831190", "35831190" ], [ "Upendra Nayek, Syed Ibrahim Basheer Ahamed, Ummul Halilunnisa Mansoor Hussain, Mazhuvancherry Kesavan Unnikrishnan, Abdul Ajees Abdul Salam (2022). Computational investigations of indanedione and indanone derivatives in drug discovery: Indanone derivatives inhibits cereblon, an E3 ubiquitin ligase component. Computational biology and chemistry, 107776. https://doi.org/10.1016/j.compbiolchem.2022.107776 PMID: 36252444", "36252444" ], [ "Sarah Gooding, Naser Ansari-Pour, Mohammad Kazeroun, Kubra Karagoz, Ann Polonskaia, Mirian Salazar, Evie Fitzsimons, Korsuk Sirinukunwattana, Selina Chavda, Maria Ortiz Estevez, Fadi Towfic, Erin Flynt, William Pierceall, Daniel Royston, Kwee Yong, Karthik Ramasamy, Paresh Vyas, Anjan Thakurta (2022). Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma. Blood, 1816-1821. https://doi.org/10.1182/blood.2022015909 PMID: 35853156", "35853156" ] ] ], [ [ "Lenalidomide", "Multiple Myeloma" ], 80.89941, [ [ "Fumiya Kaneko, Hiroshi Suzuka, Tomoaki Yoshino, Ryosuke Hinosugi (2024). Safety and Effectiveness of Elotuzumab in Japanese Patients with Relapsed/Refractory Multiple Myeloma: A Post-marketing Surveillance Study. Internal medicine (Tokyo, Japan), 3039-3048. https://doi.org/10.2169/internalmedicine.2487-23 PMID: 38494720", "38494720" ], [ "Nadine Abdallah, Shaji K Kumar (2024). New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma. Hematology/oncology clinics of North America, 511-532. https://doi.org/10.1016/j.hoc.2023.12.013 PMID: 38216384", "38216384" ], [ "Doris K Hansen, Santosh Gautam, Marie-Hélène Lafeuille, Carmine Rossi, Bronwyn Moore, Anabelle Tardif-Samson, Philippe Thompson-Leduc, Alex Z Fu, Annelore Cortoos, Shuchita Kaila, Rafael Fonseca (2024). Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma. Cancer medicine, e70308. https://doi.org/10.1002/cam4.70308 PMID: 39486091", "39486091" ], [ "Bin Wang, Wanting Qiang, Jia Yi, Shouhong Gao, Bosu Meng, Yuhui Mu, Bolong Wang, Zhipeng Wang, Xia Tao (2023). Simultaneous quantification of thalidomide, lenalidomide and pomadomide in plasma by LC-MS/MS. Journal of pharmacological and toxicological methods, 107250. https://doi.org/10.1016/j.vascn.2023.107250 PMID: 36627002", "36627002" ], [ "Rebecca W Silbermann, Timothy Martin Schmidt, Susan Bal, Binod Dhakal, Bhagirathbhai Dholaria, Eden Biltibo, Saurabh Chhabra, Smith Giri, Kelly N Godby, Sonia Gowda, Eva Medvedova, Robert F Cornell, Natalie S Callander, Luciano J Costa (2023). Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation. EJHaem, 775-778. https://doi.org/10.1002/jha2.736 PMID: 37601885", "37601885" ], [ "Simone A Minnie, Olivia G Waltner, Kathleen S Ensbey, Stuart D Olver, Alika D Collinge, David P Sester, Christine R Schmidt, Samuel Rw Legg, Shuichiro Takahashi, Nicole S Nemychenkov, Tomoko Sekiguchi, Gregory Driessens, Ping Zhang, Motoko Koyama, Andrew Spencer, Leona A Holmberg, Scott N Furlan, Antiopi Varelias, Geoffrey R Hill (2023). TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice. The Journal of clinical investigation. PMID: 36512425", "36512425" ], [ "Yachun Jia, Rui Liu, Luyi Shi, Yuandong Feng, Linlin Zhang, Ni Guo, Aili He, Guangyao Kong (2023). Integrative analysis of the prognostic value and immune microenvironment of mitophagy-related signature for multiple myeloma. BMC cancer, 859. https://doi.org/10.1186/s12885-023-11371-7 PMID: 37700273", "37700273" ], [ "John A Dougherty, Christopher T Elder (2022). Managing Multiple Myeloma in the Face of Drug-Induced Adverse Drug Reaction. Journal of pharmacy practice, 500-504. https://doi.org/10.1177/0897190020977763 PMID: 33317373", "33317373" ], [ "Damian Mikulski, Paweł Robak, Wiktoria Ryżewska, Kamila Stańczak, Kacper Kościelny, Joanna Góra-Tybor, Tadeusz Robak (2022). Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study. Journal of clinical medicine. https://doi.org/10.3390/jcm11195908 PMID: 36233774", "36233774" ], [ "Alicja Sadowska-Klasa, Mary Abba, Justyna Gajkowska-Kulik, Jan Maciej Zaucha (2022). Therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma - diagnostic and therapeutic dilemma. Acta oncologica (Stockholm, Sweden), 1126-1131. https://doi.org/10.1080/0284186X.2022.2083921 PMID: 35668607", "35668607" ] ] ], [ [ "pomalidomide", "Relapsed/refractory multiple myeloma" ], 21.58208, [ [ "Kazutaka Sunami, Shinsuke Iida, Nobuhiro Tsukada, Taku Fujii, Hitomi Kato, Ryuichi Fukushima, Satoshi Wakabayashi, Hirofumi Nakano, Sumita Roy-Ghanta, Brandon E Kremer (2024). DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma. International journal of hematology. https://doi.org/10.1007/s12185-024-03889-8 PMID: 39718747", "39718747" ], [ "Paul G Richardson, Aurore Perrot, Joseph Mikhael, Thomas Martin, Meral Beksac, Ivan Spicka, Marcelo Capra, Mattia D'Agostino, Pieter Sonneveld, Kamlesh Bisht, Taro Fukao, Rick Zhang, Keisuke Tada, Christina Tekle, Sandrine Macé, Zandra Klippel, Helgi van de Velde, Philippe Moreau (2024). Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies. Blood cancer journal, 209. https://doi.org/10.1038/s41408-024-01149-w PMID: 39609425", "39609425" ], [ "Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino (2024). The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer immunology, immunotherapy : CII, 135. https://doi.org/10.1007/s00262-024-03711-8 PMID: 38758239", "38758239" ], [ "Nami Tagami, Michihiro Uchiyama, Kenshi Suzuki, Heigoroh Shirai, Takeshi Seto, Shinsuke Iida (2024). Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan. International journal of hematology. https://doi.org/10.1007/s12185-024-03904-y PMID: 39729222", "39729222" ], [ "Jiaxin Shen, Francesca Senes, Xiaofen Wen, Patrizia Monti, Shaoze Lin, Claudia Pinna, Andrea Murtas, Luigi Podda, Giuseppina Muntone, Gianni Tidore, Claudia Arru, Luca Sanna, Salvatore Contini, Patrizia Virdis, Leonardo Antonio Sechi, Claudio Fozza (2024). Pomalidomide in patients with multiple myeloma: potential impact on the reconstitution of a functional T-cell immunity. Immunologic research, 1470-1478. https://doi.org/10.1007/s12026-024-09546-w PMID: 39316338", "39316338" ], [ "Ying Luo, Chen Li, Yuanchen Niu, Shuanzhi Wu, Jingyuan Tian, Zhiqin Hu, Jin He, Zhixin Zhang, Haiyan Liu, Yongmei Li, Tenghua Wang, Yi Fang (2024). Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis. Expert review of hematology, 127-134. https://doi.org/10.1080/17474086.2024.2326219 PMID: 38421372", "38421372" ], [ "Hang Quach, Gurdeep Parmar, Enrique M Ocio, H Miles Prince, Albert Oriol, Helen Crowther, Nobuhiro Tsukada, Pierre Bories, Sumit Madan, Nitya Nathwani, Kazutaka Sunami, Dorothee Semiond, Disa Yu, Paul Cordero, Sandrine Macé, Florence Suzan, Philippe Moreau (2024). A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica, 4078-4082. https://doi.org/10.3324/haematol.2023.284730 PMID: 39157871", "39157871" ], [ "Wenxia Fan, Lei Wang, Xinyou Wang, Ying Liu, Mingling Sun, Nadia Abduklimu, Rui Zhang, Ming Jiang, Xinhong Guo (2024). Selinexor in combination with pomalidomide and dexamethasone for the treatment of primary plasma cell leukemia with 1q21+ abnormality: A case report. Medicine, e40447. https://doi.org/10.1097/MD.0000000000040447 PMID: 39560551", "39560551" ], [ "Nami Tagami, Michihiro Uchiyama, Kenshi Suzuki, Heigoroh Shirai, Takeshi Seto, Satoshi Nishina, Shinsuke Iida (2024). Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan. International journal of hematology, 217-228. https://doi.org/10.1007/s12185-024-03800-5 PMID: 38811413", "38811413" ], [ "Faiz Anwer, Tommy Lan, Michael Dolph, Hoora Moradian, Samantha Slaff, Yu-Hsuan Shih, Derek Tang (2024). Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison. Future oncology (London, England), 1-10. https://doi.org/10.1080/14796694.2024.2426443 PMID: 39611661", "39611661" ] ] ], [ [ "E3 ubiquitin ligase", "Malignant transformation" ], 28.332904, [ [ "Zhaohua Cai, Shaojin You, Zhixue Liu, Ping Song, Fujie Zhao, Junqing An, Ye Ding, Ben He, Ming-Hui Zou (2024). Selective deletion of E3 ubiquitin ligase FBW7 in VE-cadherin-positive cells instigates diffuse large B-cell lymphoma in mice in vivo. Cell death & disease, 212. https://doi.org/10.1038/s41419-024-06597-7 PMID: 38485719", "38485719" ], [ "Robert B Kargbo (2023). Potent and Selective BCL-XL Inhibitors and PROTAC Compounds as Potential Cancer Treatment and Immunotherapy. ACS medicinal chemistry letters, 702-704. https://doi.org/10.1021/acsmedchemlett.3c00181 PMID: 37312850", "37312850" ], [ "Qianru Zhan, Jing Wang, Heyang Zhang, Lijun Zhang (2023). E3 ubiquitin ligase on the biological properties of hematopoietic stem cell. Journal of molecular medicine (Berlin, Germany), 543-556. https://doi.org/10.1007/s00109-023-02315-6 PMID: 37081103", "37081103" ], [ "Jie Xu, Pengfei Shi, Fanwei Xia, Xuan Zhao, Junfan Chen, Rui Geng, Hongjuan Cui, Liqun Yang (2022). RAI14 Promotes Melanoma Progression by Regulating the FBXO32/c-MYC Pathway. International journal of molecular sciences. https://doi.org/10.3390/ijms231912036 PMID: 36233342", "36233342" ], [ "Jian Wang, Hui Zhuang, Hui Zhang, Qian Li, Xinyi Cao, Zihan Lin, Ting Lin, Xiwei Chen, Xiaoqi Ni, Jianye Yang, Yiting Zhao, Liliang Shen, Haibiao Wang, Jie Zhu, Meng Ye, Xiaofeng Jin (2021). SPOP suppresses testicular germ cell tumors progression through ubiquitination and degradation of DPPA2. Biochemical and biophysical research communications, 55-61. https://doi.org/10.1016/j.bbrc.2021.04.002 PMID: 33862460", "33862460" ], [ "Dhanoop Manikoth Ayyathan, Praveen Koganti, Victoria Marcu-Malina, Talia Litmanovitch, Luba Trakhtenbrot, Andrea Emanuelli, Liat Apel-Sarid, Michael Blank (2020). SMURF2 prevents detrimental changes to chromatin, protecting human dermal fibroblasts from chromosomal instability and tumorigenesis. Oncogene, 3396-3410. https://doi.org/10.1038/s41388-020-1226-3 PMID: 32103168", "32103168" ], [ "Hua Wu, Tian-Yu Yang, Yi Li, Wen-Long Ye, Feng Liu, Xiao-Shun He, Jing-Ru Wang, Wen-Juan Gan, Xiu-Ming Li, Shen Zhang, Yuan-Yuan Zhao, Jian-Ming Li (2020). Tumor Necrosis Factor Receptor-Associated Factor 6 Promotes Hepatocarcinogenesis by Interacting With Histone Deacetylase 3 to Enhance c-Myc Gene Expression and Protein Stability. Hepatology (Baltimore, Md.), 148-163. https://doi.org/10.1002/hep.30801 PMID: 31155734", "31155734" ], [ "R Willow Hynes-Smith, Samantha A Swenson, Heather Vahle, Karli J Wittorf, Mika Caplan, Catalina Amador, R Katherine Hyde, Shannon M Buckley (2019). Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia. Cancers. https://doi.org/10.3390/cancers11111717 PMID: 31684170", "31684170" ], [ "M Brodhun, V Stahn, A Harder (2017). [Pathogenesis and molecular pathology of vestibular schwannoma]. HNO, 362-372. https://doi.org/10.1007/s00106-016-0201-3 PMID: 27421984", "27421984" ], [ "Wenfu Lu, Shenji Liu, Bo Li, Yingqiu Xie, Christine Adhiambo, Qing Yang, Billy R Ballard, Keiichi I Nakayama, Robert J Matusik, Zhenbang Chen (2015). SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination. Oncotarget, 771-88. https://doi.org/10.18632/oncotarget.2718 PMID: 25596733", "25596733" ] ] ], [ [ "pomalidomide", "Multiple Myeloma" ], 113.465406, [ [ "Holly Lee, Paola Neri, Nizar J Bahlis (2024). Cereblon-Targeting Ligase Degraders in Myeloma: Mechanisms of Action and Resistance. Hematology/oncology clinics of North America, 305-319. https://doi.org/10.1016/j.hoc.2024.01.001 PMID: 38302306", "38302306" ], [ "Katja Weisel, Meletios A Dimopoulos, Meral Beksac, Xavier Leleu, Joshua Richter, Bart Heeg, Sachin Patel, Istvan Majer, Ian McFadden, Joseph Mikhael (2024). Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison. Leukemia & lymphoma, 481-492. https://doi.org/10.1080/10428194.2023.2300051 PMID: 38345269", "38345269" ], [ "Danka Cholujova, Zdenka Lukacova Bujnakova, Erika Dutkova, Zuzana Valuskova, Nikoleta Csicsatkova, Katarina Suroviakova, Maria Elisabeth Marinkovicova, Linda Zbellova, Lenka Koklesova, Jan Sedlak, Teru Hideshima, Kenneth C Anderson, Jana Jakubikova (2024). Exploring the anti-myeloma potential of composite nanoparticles As4S4/Fe3O4: Insights from in vitro, ex vivo and in vivo studies. Nanomedicine : nanotechnology, biology, and medicine, 102777. https://doi.org/10.1016/j.nano.2024.102777 PMID: 39111377", "39111377" ], [ "Doris K Hansen, Xiaoxiao Lu, Omar Castaneda Puglianini, Sonja Sorensen, Saad Z Usmani, Eileen Zhang, Stephen Huo, Yan Zhang, Zaina P Qureshi, Sundar Jagannath (2024). Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4. Frontiers in immunology, 1408892. https://doi.org/10.3389/fimmu.2024.1408892 PMID: 39234256", "39234256" ], [ "Aleksandra Marciniak, Edward Krzyżak, Dominika Szkatuła, Krystian Mazurkiewicz, Aleksandra Kotynia (2024). A Spectroscopic and In Silico Description of the Non-Covalent Interactions of Phthalic Acid Imide Derivatives with Deoxyribonucleic Acid-Insights into Their Binding Characteristics and Potential Applications. Molecules (Basel, Switzerland). https://doi.org/10.3390/molecules29225422 PMID: 39598811", "39598811" ], [ "Nadine Abdallah, Shaji K Kumar (2024). New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma. Hematology/oncology clinics of North America, 511-532. https://doi.org/10.1016/j.hoc.2023.12.013 PMID: 38216384", "38216384" ], [ "Alejandro Meraz-Munoz, Hira Mian, David Kirkwood, Nivethika Jeyakumar, Arleigh McCurdy, Navdeep Tangri, Refik Saskin, Nelson Leung, Ron Wald, Abhijat Kitchlu (2024). Pomalidomide Use and Kidney Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study. Clinical lymphoma, myeloma & leukemia, e861-e869. https://doi.org/10.1016/j.clml.2024.07.007 PMID: 39117532", "39117532" ], [ "Hitomi Nakayama, Yoshinobu Aisa, Chisako Ito, Aki Sakurai, Tomonori Nakazato (2024). The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone. Hematology reports, 593-602. https://doi.org/10.3390/hematolrep16040058 PMID: 39449301", "39449301" ], [ "(2024). Jian Y, Chang L, Shi M-X, et al. Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment. Blood Adv. 2023;7(24):7581-7584. Blood advances, 1991. https://doi.org/10.1182/bloodadvances.2024013036 PMID: 38619856", "38619856" ], [ "Esteban Zavaleta-Monestel, Ricardo Quesada-Villaseñor, Monserrat Barrantes-López, Sebastián Arguedas-Chacón, Jeimy Campos-Hernández, Carolina Rojas-Chinchilla, Jonathan García-Montero, Josué Castro-Ulloa, Adriana Anchía-Alfaro, José Ricardo Montenegro-Chaves (2024). Advancements in the Treatment of Multiple Myeloma. Cureus, e74970. https://doi.org/10.7759/cureus.74970 PMID: 39744254", "39744254" ] ] ], [ [ "E3 ubiquitin ligase", "Malignant Neoplasms" ], 44.006348, [ [ "Shinichiro Matsui, Chihiro Ri, Lyndsey C Bolanos, Kwangmin Choi, Asuka Shibamiya, Arata Ishii, Koji Takaishi, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto, Yusuke Takeda, Naoya Mimura, Akihide Yoshimi, Koutaro Yokote, Daniel T Starczynowski, Emiko Sakaida, Tomoya Muto (2024). Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression. Leukemia, 1032-1045. https://doi.org/10.1038/s41375-024-02245-3 PMID: 38609495", "38609495" ], [ "Mingyang Cheng, Bin Xu, Yu Sun, Junhong Wang, Yiyuan Lu, Chunwei Shi, Tianxu Pan, Wenhui Zhao, Xiaoxu Li, Xiaomei Song, Jianzhong Wang, Nan Wang, Wentao Yang, Yanlong Jiang, Haibin Huang, Guilian Yang, Yan Zeng, Dongqin Yang, Chunfeng Wang, Xin Cao (2024). ASB3 expression aggravates inflammatory bowel disease by targeting TRAF6 protein stability and affecting the intestinal microbiota. mBio, e0204324. https://doi.org/10.1128/mbio.02043-24 PMID: 39162488", "39162488" ], [ "Hiroyuki Inuzuka, Chao Qian, Yihang Qi, Yan Xiong, Chaoyu Wang, Zhen Wang, Dingpeng Zhang, Can Zhang, Jian Jin, Wenyi Wei (2024). Targeted Degradation of Receptor-Interacting Protein Kinase 1 to Modulate the Necroptosis Pathway. ACS pharmacology & translational science, 3518-3526. https://doi.org/10.1021/acsptsci.4c00421 PMID: 39539258", "39539258" ], [ "Liang Zeng, Ying-Qing Li, Shi-Wei He, Hui Xu, Ruizhong Zhang, Kai Chen, Liang-Jun Qin, Xun-Hua Zhu, Yi-Lin Li, Le Li, Na Liu, Hai-Yun Wang (2024). The deubiquitinase USP44 enhances cisplatin chemosensitivity through stabilizing STUB1 to promote LRPPRC degradation in neuroblastoma. Neuro-oncology. https://doi.org/10.1093/neuonc/noae175 PMID: 39215663", "39215663" ], [ "Satsuki Ryu, Hiroki Nakashima, Yuka Tanaka, Risa Mukai, Yasuhiro Ishihara, Takashi Tominaga, Takayuki Ohshima (2024). Ribosomal Protein S4 X-Linked as a Novel Modulator of MDM2 Stability by Suppressing MDM2 Auto-Ubiquitination and SCF Complex-Mediated Ubiquitination. Biomolecules. https://doi.org/10.3390/biom14080885 PMID: 39199272", "39199272" ], [ "Hao Zhang, Yujia Zheng, Zhen Wang, Lin Dong, Liyan Xue, Xiaolin Tian, Haiteng Deng, Qi Xue, Shugeng Gao, Yibo Gao, Chunxiang Li, Jie He (2024). KLF12 interacts with TRIM27 to affect cisplatin resistance and cancer metastasis in esophageal squamous cell carcinoma by regulating L1CAM expression. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 101096. https://doi.org/10.1016/j.drup.2024.101096 PMID: 38924996", "38924996" ], [ "Guirong Luo, Liting Zhang, Lihong Zhang, Wenyi Wu, Jianqing Lin, Haihong Shi, Yihuang Yu, Weigang Qiu, Jinyan Chen, Hansen Ding, Xinyao Chen (2024). Tumor‑suppressive effects of Smad‑ubiquitination regulator 2 in papillary thyroid carcinoma. Oncology letters, 263. https://doi.org/10.3892/ol.2024.14396 PMID: 38646500", "38646500" ], [ "Yawen Liu, Juanjuan Zhou, Weiqi Liu, Yi Le, Lingling Zhang, Ziyu Zhang, Ling Zhou, Ling Li (2024). The E3 ubiquitin ligase RNF6 facilitates the progression of cervical cancer by inhibiting the Hippo/Yap pathway. Cell division, 32. https://doi.org/10.1186/s13008-024-00136-8 PMID: 39551725", "39551725" ], [ "Jeetendra Kumar Nag, Priyanga Appasamy, Hodaya Malka, Shoshana Sedley, Rachel Bar-Shavit (2024). New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies. International journal of molecular sciences. https://doi.org/10.3390/ijms25158083 PMID: 39125653", "39125653" ], [ "Pei Wen, Huiyan Lei, Hua Deng, Su Deng, Carla Rodriguez Tirado, Meiling Wang, Ping Mu, Yonggang Zheng, Duojia Pan (2024). Hyd/UBR5 defines a tumor suppressor pathway that links Polycomb repressive complex to regulated protein degradation in tissue growth control and tumorigenesis. Genes & development, 675-691. https://doi.org/10.1101/gad.351856.124 PMID: 39137945", "39137945" ] ] ], [ [ "Lenalidomide", "Malignant Neoplasms" ], 31.147871000000002, [ [ "Shuang Qu, Li-Sheng Liao, Yan-Bin Zheng, Jie-Song Wang, Hong-Ming He, Bi-Yun Chen, Hong Sun (2024). [Different Prophylaxis Strategies for Central Nervous System Recurrence of Diffuse Large B-Cell Lymphoma]. Zhongguo shi yan xue ye xue za zhi, 1407-1413. https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.05.015 PMID: 39479823", "39479823" ], [ "Afsaneh Moghaddam Jafari, Ali Morsali, Mohammad Reza Bozorgmehr, S Ali Beyramabadi, Sharareh Mohseni (2024). Modeling and characterization of lenalidomide-loaded tripolyphosphate-crosslinked chitosan nanoparticles for anticancer drug delivery. International journal of biological macromolecules, 129360. https://doi.org/10.1016/j.ijbiomac.2024.129360 PMID: 38218265", "38218265" ], [ "Aleksandra Marciniak, Edward Krzyżak, Dominika Szkatuła, Krystian Mazurkiewicz, Aleksandra Kotynia (2024). A Spectroscopic and In Silico Description of the Non-Covalent Interactions of Phthalic Acid Imide Derivatives with Deoxyribonucleic Acid-Insights into Their Binding Characteristics and Potential Applications. Molecules (Basel, Switzerland). https://doi.org/10.3390/molecules29225422 PMID: 39598811", "39598811" ], [ "Mitchell R Smith, Opeyemi A Jegede, Peter Martin, Brian G Till, Samir S Parekh, David T Yang, Eric D Hsi, Thomas Witzig, Sandeep Dave, David Scott, Curtis Hanson, Lale Kostakoglu Shields, Nizar Abdel-Samad, Carla Casulo, Nancy L Bartlett, Paolo F Caimi, Tareq Al Baghdadi, Kristie A Blum, Mark D Romer, David J Inwards, Rachel E Lerner, Lynne I Wagner, Richard F Little, Jonathan W Friedberg, John P Leonard, Brad S Kahl (2024). Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL. Blood, 1083-1092. https://doi.org/10.1182/blood.2024023962 PMID: 38820500", "38820500" ], [ "Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda, Gemlyn George, Marcos de Lima, Shahrukh Hashmi, Mohamed A Kharfan-Dabaja, Navneet S Majhail, Rahul Banerjee, Ayman Saad, Gerhard C Hildebrandt, Hira Mian, Muhammad Bilal Abid, Minoo Battiwalla, Lazaros J Lekakis, Sagar S Patel, Hemant S Murthy, Yago Nieto, Christopher Strouse, Sherif M Badawy, Samer Al Hadidi, Bhagirathbhai Dholaria, Mahmoud Aljurf, David H Vesole, Cindy H Lee, Attaphol Pawarode, Usama Gergis, Kevin C Miller, Leona A Holmberg, Aimaz Afrough, Melhem Solh, Pashna N Munshi, Taiga Nishihori, Larry D Anderson, Baldeep Wirk, Gurbakhash Kaur, Muzaffar H Qazilbash, Nina Shah, Shaji K Kumar, Saad Z Usmani (2023). Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood advances, 2746-2757. https://doi.org/10.1182/bloodadvances.2022009138 PMID: 36827681", "36827681" ], [ "Seth J Welsh, Benjamin G Barwick, Erin W Meermeier, Daniel L Riggs, Chang-Xin Shi, Yuan Xiao Zhu, Meaghen E Sharik, Megan T Du, Leslie D Abrego Rocha, Victoria M Garbitt, Caleb K Stein, Joachim L Petit, Nathalie Meurice, Yuliza Tafoya Alvarado, Rodrigo Fonseca, Kennedi T Todd, Sochilt Brown, Zachary J Hammond, Nicklus H Cuc, Courtney Wittenberg, Camille Herzog, Anna V Roschke, Yulia N Demchenko, Wei-Dong D Chen, Peng Li, Wei Liao, Warren J Leonard, Sagar Lonial, Nizar J Bahlis, Paola Neri, Lawrence H Boise, Marta Chesi, P Leif Bergsagel (2023). Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma. Blood cancer discovery. https://doi.org/10.1158/2643-3230.BCD-23-0062 PMID: 37767768", "37767768" ], [ "Hua-Jay J Cherng, Stefan K Alig, Yasuhiro Oki, Loretta J Nastoupil, Luis Fayad, Sattva S Neelapu, Francesco Turturro, Fredrick Hagemeister, Alexander F M Craig, Charles W Macaulay, Maria Alma Rodriguez, Hun Ju Lee, Timothy J McDonnell, Christopher R Flowers, Francisco Vega, Michael R Green, Lei Feng, David M Kurtz, Ash A Alizadeh, R Eric Davis, Jason R Westin (2023). A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood advances, 1137-1145. https://doi.org/10.1182/bloodadvances.2022008174 PMID: 36375046", "36375046" ], [ "Daniel T Gildea, Joseph L Roswarski (2023). Severe Lenalidomide-Associated Hyperbilirubinemia. Cureus, e34408. https://doi.org/10.7759/cureus.34408 PMID: 36874759", "36874759" ], [ "Sean Henry Jackewicz, Helena S Coloma, Viviana Cortiana, Muskan Joshi, Gayathri P Menon, Maduri Balasubramanian, Chandler H Park, Yan Leyfman (2023). The Evolving Landscape: Exploring the Future of Myelodysplastic Syndrome Treatment with Dr. Rami Komrokji. Cancers. https://doi.org/10.3390/cancers15215170 PMID: 37958344", "37958344" ], [ "Yachun Jia, Rui Liu, Luyi Shi, Yuandong Feng, Linlin Zhang, Ni Guo, Aili He, Guangyao Kong (2023). Integrative analysis of the prognostic value and immune microenvironment of mitophagy-related signature for multiple myeloma. BMC cancer, 859. https://doi.org/10.1186/s12885-023-11371-7 PMID: 37700273", "37700273" ] ] ], [ [ "Thalidomide", "Malignant Neoplasms" ], 32.93064, [ [ "Iftekhar Hossain Chowdhury, Shamima Rahman, Yeasmin Jahan Afroze, Sharmeen Tania Shovah (2024). IUPHAR ECR review: Cancer-related anorexia-cachexia in cancer patients: Pathophysiology and treatment. Pharmacological research, 107129. https://doi.org/10.1016/j.phrs.2024.107129 PMID: 38461961", "38461961" ], [ "Aleksandra Marciniak, Edward Krzyżak, Dominika Szkatuła, Krystian Mazurkiewicz, Aleksandra Kotynia (2024). A Spectroscopic and In Silico Description of the Non-Covalent Interactions of Phthalic Acid Imide Derivatives with Deoxyribonucleic Acid-Insights into Their Binding Characteristics and Potential Applications. Molecules (Basel, Switzerland). https://doi.org/10.3390/molecules29225422 PMID: 39598811", "39598811" ], [ "Deiwakor Chyrmang, Yumkhaibam S Devi, Kishalay Baidya, Laishram J Singh, Daffilyne L Nongrum, Ningthoujam D Devi (2024). A comparative study of whole brain radiotherapy with concomitant thalidomide versus whole brain radiotherapy alone in brain metastases. Journal of cancer research and therapeutics, 255-260. https://doi.org/10.4103/jcrt.jcrt_1724_22 PMID: 38554330", "38554330" ], [ "Daniel T Gildea, Joseph L Roswarski (2023). Severe Lenalidomide-Associated Hyperbilirubinemia. Cureus, e34408. https://doi.org/10.7759/cureus.34408 PMID: 36874759", "36874759" ], [ "Camille Winnicki, Pierre Leblond, Franck Bourdeaut, Anne Pagnier, Gilles Paluenzela, Pascal Chastagner, Gwenaelle Duhil-De Benaze, Victoria Min, Hélène Sudour-Bonnange, Catherine Piette, Natacha Entz-Werle, Sylvie Chabaud, Nicolas André (2023). Retrospective National \"Real Life\" Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol. Journal of clinical medicine. https://doi.org/10.3390/jcm12041415 PMID: 36835950", "36835950" ], [ "Victor Yu Han Ling, Sreekanth Reddivari, Angel Mary Joseph, Rosie Cox (2022). Oligosecretory myeloma with gastrointestinal tract involvement: an unusual presentation and literature review. BMJ case reports. https://doi.org/10.1136/bcr-2021-247742 PMID: 35365468", "35365468" ], [ "Krishna V Suresh, Amy L Xu, Mari L Groves, Paul D Sponseller (2022). Spinal screening, malignancy, medical therapy, and surgical correction of deformity in pediatric patients with neurofibromatosis type 1: a systematic review. Journal of pediatric orthopedics. Part B, 572-582. https://doi.org/10.1097/BPB.0000000000000961 PMID: 35132000", "35132000" ], [ "Leifeng Liang, Liangwen Chen, Gongwei Liu, Liujun Jiang, Lilin Que, Jie Chen, Rensheng Wang, Haisheng Zhu (2022). Thalidomide attenuates oral epithelial cell apoptosis and pro-inflammatory cytokines secretion induced by radiotherapy via the miR-9-3p/NFATC2/NF-κB axis. Biochemical and biophysical research communications, 102-108. https://doi.org/10.1016/j.bbrc.2022.03.030 PMID: 35279460", "35279460" ], [ "Alexia Barbarossa, Domenico Iacopetta, Maria Stefania Sinicropi, Carlo Franchini, Alessia Carocci (2022). Recent Advances in the Development of Thalidomide-Related Compounds as Anticancer Drugs. Current medicinal chemistry, 19-40. https://doi.org/10.2174/0929867328666210623143526 PMID: 34165402", "34165402" ], [ "Adriana Romo-Perez, Guadalupe Dominguez-Gomez, Alma Chavez-Blanco, Lucia Taja-Chayeb, Aurora Gonzalez-Fierro, Elisa Garcia-Martinez, Jose Correa-Basurto, Alfonso Duenas-Gonzalez (2022). BAPST. A Combo of Common Use Drugs as Metabolic Therapy for Cancer: A Theoretical Proposal. Current molecular pharmacology, 815-831. https://doi.org/10.2174/1874467214666211006123728 PMID: 34620071", "34620071" ] ] ], [ [ "pomalidomide", "Malignant Neoplasms" ], 24.575297, [ [ "Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf, Monique C Minnema, Leyla Shune, Iris Isufi, Simon J Harrison, Urvi A Shah, Jordan M Schecter, Martin Vogel, Nikoletta Lendvai, Katharine S Gries, Eva G Katz, Ana Slaughter, Carolina Lonardi, Jane Gilbert, Quanlin Li, William Deraedt, Octavio Costa Filho, Nitin Patel, Erika Florendo, Lionel Karlin, Katja Weisel (2025). Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. The Lancet. Haematology, e45-e56. https://doi.org/10.1016/S2352-3026(24)00320-X PMID: 39756844", "39756844" ], [ "Christos Siokatas, Alexandra Lampropoulou, Alexandra Smina, Katerina Soupsana, Martha Kontostathi, Athina-Vasiliki Karra, Theodoros Karampelas, Anastasia S Politou, Savvas Christoforidis, Constantin Tamvakopoulos, Vasiliki Sarli (2024). Developing MYC Degraders Bearing the Von Hippel-Lindau Ligand to Target the \"Undruggable\" MYC. ACS pharmacology & translational science, 3955-3968. https://doi.org/10.1021/acsptsci.4c00452 PMID: 39698270", "39698270" ], [ "Bei Zhang, Dawei Hong, Hujuan Qian, Keqing Ma, Liquan Zhu, Linye Jiang, Jingyan Ge (2024). Unveiling a new strategy for PDIA1 inhibition: Integration of activity-based probes profiling and targeted degradation. Bioorganic chemistry, 107585. https://doi.org/10.1016/j.bioorg.2024.107585 PMID: 38917491", "38917491" ], [ "Wenxia Fan, Lei Wang, Xinyou Wang, Ying Liu, Mingling Sun, Nadia Abduklimu, Rui Zhang, Ming Jiang, Xinhong Guo (2024). Selinexor in combination with pomalidomide and dexamethasone for the treatment of primary plasma cell leukemia with 1q21+ abnormality: A case report. Medicine, e40447. https://doi.org/10.1097/MD.0000000000040447 PMID: 39560551", "39560551" ], [ "Di Chen, Shuxian Lin, Ziwei Zeng, Jianxiong An, Wanli Yan, Zhicheng Gu, Lei Chen, Bin He (2024). Serendipitous discovery of Class I HDAC inhibitors from rational design of molecular glue degraders targeting HDAC. European journal of medicinal chemistry, 115926. https://doi.org/10.1016/j.ejmech.2023.115926 PMID: 37995564", "37995564" ], [ "Aleksandra Marciniak, Edward Krzyżak, Dominika Szkatuła, Krystian Mazurkiewicz, Aleksandra Kotynia (2024). A Spectroscopic and In Silico Description of the Non-Covalent Interactions of Phthalic Acid Imide Derivatives with Deoxyribonucleic Acid-Insights into Their Binding Characteristics and Potential Applications. Molecules (Basel, Switzerland). https://doi.org/10.3390/molecules29225422 PMID: 39598811", "39598811" ], [ "Po-Chang Shih, Miyako Naganuma, Genichiro Tsuji, Yosuke Demizu, Mikihiko Naito (2023). Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3. Bioorganic & medicinal chemistry, 117507. https://doi.org/10.1016/j.bmc.2023.117507 PMID: 37922656", "37922656" ], [ "Richa Vartak, Bhavesh Deore, Carlos A Sanhueza, Ketan Patel (2023). Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations. International journal of biological macromolecules, 126413. https://doi.org/10.1016/j.ijbiomac.2023.126413 PMID: 37598823", "37598823" ], [ "Katherine O Kopp, Margaret E Greer, Elliot J Glotfelty, Shih-Chang Hsueh, David Tweedie, Dong Seok Kim, Marcella Reale, Neil Vargesson, Nigel H Greig (2023). A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders. Biomolecules. https://doi.org/10.3390/biom13050747 PMID: 37238617", "37238617" ], [ "Catherine B Goff, Constantin A Dasanu (2023). Changing therapeutic landscape in advanced Kaposi sarcoma: Current state and future directions. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 917-926. https://doi.org/10.1177/10781552221148417 PMID: 36718515", "36718515" ] ] ], [ [ "Dexamethasone", "Multiple Myeloma" ], 38.404316, [ [ "Krzysztof Jamroziak, Klaudia Zielonka, Jahanzaib Khwaja, Ashutosh D Wechalekar (2025). Update on B-cell maturation antigen-directed therapies in AL amyloidosis. British journal of haematology. https://doi.org/10.1111/bjh.19960 PMID: 39748220", "39748220" ], [ "Fumiya Kaneko, Hiroshi Suzuka, Tomoaki Yoshino, Ryosuke Hinosugi (2024). Safety and Effectiveness of Elotuzumab in Japanese Patients with Relapsed/Refractory Multiple Myeloma: A Post-marketing Surveillance Study. Internal medicine (Tokyo, Japan), 3039-3048. https://doi.org/10.2169/internalmedicine.2487-23 PMID: 38494720", "38494720" ], [ "Zeki Toprak, Ezgi Ersoy Yesil, Fatima Zerenler Gursoy, Hakan Keski, Hasan Kayabasi, Dede Sit, Eyup V Kucuk (2024). A Case of Primary Renal Allograft Dysfunction Caused by Missed Monoclonal Disease. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 572-575. https://doi.org/10.6002/ect.2023.0155 PMID: 39223816", "39223816" ], [ "Nader Slama, Inaam Bizid, Ahlem Bellalah, Mabrouk Abdelali, Mohamed Adnene Laatiri (2024). Extramedullary plasmacytoma of the orbit complicating the evolution of multiple myeloma in complete remission. Leukemia research reports, 100460. https://doi.org/10.1016/j.lrr.2024.100460 PMID: 38707773", "38707773" ], [ "Nadine Abdallah, Shaji K Kumar (2024). New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma. Hematology/oncology clinics of North America, 511-532. https://doi.org/10.1016/j.hoc.2023.12.013 PMID: 38216384", "38216384" ], [ "Rebecca W Silbermann, Timothy Martin Schmidt, Susan Bal, Binod Dhakal, Bhagirathbhai Dholaria, Eden Biltibo, Saurabh Chhabra, Smith Giri, Kelly N Godby, Sonia Gowda, Eva Medvedova, Robert F Cornell, Natalie S Callander, Luciano J Costa (2023). Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation. EJHaem, 775-778. https://doi.org/10.1002/jha2.736 PMID: 37601885", "37601885" ], [ "Tahani Atieh, Shebli Atrash, Nausheen Ahmed, Meera Mohan, Wei Cui, Leyla Shune, Susana Hajjar, Zahra Mahmoudjafari, Julie Quick, Anne Wishna, Justin Riffel, Joseph McGuirk, Ghulam Rehman Mohyuddin, Al-Ola Abdallah (2022). Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 912-919. https://doi.org/10.1016/j.clml.2022.08.003 PMID: 36127271", "36127271" ], [ "John A Dougherty, Christopher T Elder (2022). Managing Multiple Myeloma in the Face of Drug-Induced Adverse Drug Reaction. Journal of pharmacy practice, 500-504. https://doi.org/10.1177/0897190020977763 PMID: 33317373", "33317373" ], [ "Damian Mikulski, Paweł Robak, Wiktoria Ryżewska, Kamila Stańczak, Kacper Kościelny, Joanna Góra-Tybor, Tadeusz Robak (2022). Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study. Journal of clinical medicine. https://doi.org/10.3390/jcm11195908 PMID: 36233774", "36233774" ], [ "Karthik Ramasamy, Gulnaz Iqbal, Richard Brouwer, Victoria Stalker, Salma Akhtar, Sherin Varghese, Jindriska Lindsay, Stephen Schey, Mark Drayson, Janet Dunn (2022). Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial. Blood cancer journal, 162. https://doi.org/10.1038/s41408-022-00758-7 PMID: 36446771", "36446771" ] ] ], [ [ "E3 ubiquitin ligase", "Dexamethasone" ], 28.16656, [ [ "Hyeonjin Hur, Hye-Jin Kim, Dongheon Lee, Cheorun Jo (2024). Beef peptides mitigate skeletal muscle atrophy in C2C12 myotubes through protein degradation, protein synthesis, and the oxidative stress pathway. Food & function, 4564-4574. https://doi.org/10.1039/d3fo03911k PMID: 38584588", "38584588" ], [ "Kosuke Nakagawara, Chieri Takeuchi, Kazuya Ishige (2023). 5'-CMP and 5'-UMP alleviate dexamethasone-induced muscular atrophy in C2C12 myotubes. Biochemistry and biophysics reports, 101460. https://doi.org/10.1016/j.bbrep.2023.101460 PMID: 37020790", "37020790" ], [ "Qi Li, Zhao-di Kong, Huan Wang, Hong-Hui Gu, Zhong Chen, Shi-Guang Li, Yi-Qi Chen, Yu Cai, Zhen-Jiang Yang (2023). Jianpi Decoction Combined with Medroxyprogesterone Acetate Alleviates Cancer Cachexia and Prevents Muscle Atrophy by Directly Inhibiting E3 Ubiquitin Ligase. Chinese journal of integrative medicine. https://doi.org/10.1007/s11655-023-3702-4 PMID: 37612478", "37612478" ], [ "Paul G Richardson, Suzanne Trudel, Rakesh Popat, María-Victoria Mateos, Annette J Vangsted, Karthik Ramasamy, Joaquín Martinez-Lopez, Hang Quach, Robert Z Orlowski, Mario Arnao, Sagar Lonial, Chatchada Karanes, Charlotte Pawlyn, Kihyun Kim, Albert Oriol, Jesus G Berdeja, Paula Rodríguez Otero, Ignacio Casas-Avilés, Alessia Spirli, Jennifer Poon, Shaoyi Li, Jing Gong, Lilly Wong, Manisha Lamba, Daniel W Pierce, Michael Amatangelo, Teresa Peluso, Paulo Maciag, Jessica Katz, Michael Pourdehnad, Nizar J Bahlis, (2023). Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. The New England journal of medicine, 1009-1022. https://doi.org/10.1056/NEJMoa2303194 PMID: 37646702", "37646702" ], [ "Bert Kwanten, Tine Deconick, Christopher Walker, Feng Wang, Yosef Landesman, Dirk Daelemans (2023). E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 114305. https://doi.org/10.1016/j.biopha.2023.114305 PMID: 36731340", "36731340" ], [ "Tiffany Yip Delormel, Liliana Avila-Ospina, Marlène Davanture, Michel Zivy, Julien Lang, Nicolas Valentin, Naganand Rayapuram, Heribert Hirt, Jean Colcombet, Marie Boudsocq (2022). In vivo identification of putative CPK5 substrates in Arabidopsis thaliana. Plant science : an international journal of experimental plant biology, 111121. https://doi.org/10.1016/j.plantsci.2021.111121 PMID: 34895550", "34895550" ], [ "Ibotombi Singh Sinam, Dipanjan Chanda, Themis Thoudam, Min-Ji Kim, Byung-Gyu Kim, Hyeon-Ji Kang, Jung Yi Lee, Seung-Hoon Baek, Shin-Yoon Kim, Bum Jin Shim, Dongryeol Ryu, Jae-Han Jeon, In-Kyu Lee (2022). Pyruvate dehydrogenase kinase 4 promotes ubiquitin-proteasome system-dependent muscle atrophy. Journal of cachexia, sarcopenia and muscle, 3122-3136. https://doi.org/10.1002/jcsm.13100 PMID: 36259412", "36259412" ], [ "Tania Cid-Díaz, Saúl Leal-López, Fátima Fernández-Barreiro, Jessica González-Sánchez, Icía Santos-Zas, Luis J Andrade-Bulos, Manuel E Rodríguez-Fuentes, Carlos S Mosteiro, Vincent Mouly, Xesús Casabiell, Jose Luis Relova, Yolanda Pazos, Jesus P Camiña (2021). Obestatin signalling counteracts glucocorticoid-induced skeletal muscle atrophy via NEDD4/KLF15 axis. Journal of cachexia, sarcopenia and muscle, 493-505. https://doi.org/10.1002/jcsm.12677 PMID: 33687156", "33687156" ], [ "Jianxuan Zou, Richard J Jones, Hua Wang, Isere Kuiatse, Fazal Shirazi, Elisabet E Manasanch, Hans C Lee, Robert Sullivan, Leah Fung, Normand Richard, Paul Erdman, Eduardo Torres, David Hecht, Imelda Lam, Brooke McElwee, Aparajita H Chourasia, Kyle W H Chan, Frank Mercurio, David I Stirling, Robert Z Orlowski (2020). The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance. Journal of molecular medicine (Berlin, Germany), 1161-1173. https://doi.org/10.1007/s00109-020-01943-6 PMID: 32632752", "32632752" ], [ "Hiroyasu Sakai, Minami Kimura, Yuka Tsukimura, Saori Yabe, Yosuke Isa, Yuki Kai, Fumiaki Sato, Risako Kon, Nobutomo Ikarashi, Minoru Narita, Yoshihiko Chiba, Junzo Kamei (2019). Dexamethasone exacerbates cisplatin-induced muscle atrophy. Clinical and experimental pharmacology & physiology, 19-28. https://doi.org/10.1111/1440-1681.13024 PMID: 30137654", "30137654" ] ] ], [ [ "E3 ubiquitin ligase", "Neoplasms" ], 43.964606, [ [ "Chunli Song, Zijun Jiao, Zhanfeng Hou, Yun Xing, Xinrui Sha, Yuechen Wang, Jiaxin Chen, Susheng Liu, Zigang Li, Feng Yin (2024). Versatile Split-and-Mix Liposome PROTAC Platform for Efficient Degradation of Target Protein In Vivo. JACS Au, 2915-2924. https://doi.org/10.1021/jacsau.4c00278 PMID: 39211615", "39211615" ], [ "Erika P Hamilton, Cynthia Ma, Michelino De Laurentiis, Hiroji Iwata, Sara A Hurvitz, Seth A Wander, Michael Danso, Dongrui R Lu, Julia Perkins Smith, Yuan Liu, Lana Tran, Sibyl Anderson, Mario Campone (2024). VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future oncology (London, England), 2447-2455. https://doi.org/10.1080/14796694.2024.2377530 PMID: 39072356", "39072356" ], [ "Gerhard Hamilton, Marie-Therese Eggerstorfer, Sandra Stickler (2024). Development of PROTACS degrading KRAS and SOS1. Oncology research, 1257-1264. https://doi.org/10.32604/or.2024.051653 PMID: 39055890", "39055890" ], [ "Liang Zeng, Ying-Qing Li, Shi-Wei He, Hui Xu, Ruizhong Zhang, Kai Chen, Liang-Jun Qin, Xun-Hua Zhu, Yi-Lin Li, Le Li, Na Liu, Hai-Yun Wang (2024). The deubiquitinase USP44 enhances cisplatin chemosensitivity through stabilizing STUB1 to promote LRPPRC degradation in neuroblastoma. Neuro-oncology. https://doi.org/10.1093/neuonc/noae175 PMID: 39215663", "39215663" ], [ "Satsuki Ryu, Hiroki Nakashima, Yuka Tanaka, Risa Mukai, Yasuhiro Ishihara, Takashi Tominaga, Takayuki Ohshima (2024). Ribosomal Protein S4 X-Linked as a Novel Modulator of MDM2 Stability by Suppressing MDM2 Auto-Ubiquitination and SCF Complex-Mediated Ubiquitination. Biomolecules. https://doi.org/10.3390/biom14080885 PMID: 39199272", "39199272" ], [ "Zhe Hu, Yilin Wu, Xiaoou Sun, Yanli Tong, Houkuang Qiu, Enqing Zhuo (2024). ARMCX1 inhibits lung adenocarcinoma progression by recruiting FBXW7 for c-Myc degradation. Biology direct, 82. https://doi.org/10.1186/s13062-024-00532-8 PMID: 39285446", "39285446" ], [ "Lawrence B Snyder, Taavi K Neklesa, Ryan R Willard, Deborah A Gordon, Jennifer Pizzano, Nicholas Vitale, Kaitlynn Robling, Madeline A Dorso, Walid Moghrabi, Sean Landrette, Richard Gedrich, Sang Hyun Lee, Ian C A Taylor, John G Houston (2024). Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader. Molecular cancer therapeutics. https://doi.org/10.1158/1535-7163.MCT-23-0655 PMID: 39670468", "39670468" ], [ "Guirong Luo, Liting Zhang, Lihong Zhang, Wenyi Wu, Jianqing Lin, Haihong Shi, Yihuang Yu, Weigang Qiu, Jinyan Chen, Hansen Ding, Xinyao Chen (2024). Tumor‑suppressive effects of Smad‑ubiquitination regulator 2 in papillary thyroid carcinoma. Oncology letters, 263. https://doi.org/10.3892/ol.2024.14396 PMID: 38646500", "38646500" ], [ "Yitong Huang, Chenxiang Pan, Suni Wu, Feng Ye, Lihua Yang (2024). A combination of cuproptosis and lncRNAs predicts the prognosis and tumor immune microenvironment in cervical cancer. Discover oncology, 116. https://doi.org/10.1007/s12672-024-00964-8 PMID: 38609663", "38609663" ], [ "Yawen Liu, Juanjuan Zhou, Weiqi Liu, Yi Le, Lingling Zhang, Ziyu Zhang, Ling Zhou, Ling Li (2024). The E3 ubiquitin ligase RNF6 facilitates the progression of cervical cancer by inhibiting the Hippo/Yap pathway. Cell division, 32. https://doi.org/10.1186/s13008-024-00136-8 PMID: 39551725", "39551725" ] ] ], [ [ "pomalidomide", "Plasma cell myeloma refractory" ], 64.90937600000001, [ [ "Nami Tagami, Michihiro Uchiyama, Kenshi Suzuki, Heigoroh Shirai, Takeshi Seto, Shinsuke Iida (2024). Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan. International journal of hematology. https://doi.org/10.1007/s12185-024-03904-y PMID: 39729222", "39729222" ], [ "Antoine Pitoy, Solène Desmée, François Riglet, Hoai-Thu Thai, Zandra Klippel, Dorothée Semiond, Christine Veyrat-Follet, Julie Bertrand (2024). Isatuximab-dexamethasone-pomalidomide combination effects on serum M protein and PFS in myeloma: Development of a joint model using phase I/II data. CPT: pharmacometrics & systems pharmacology, 2087-2101. https://doi.org/10.1002/psp4.13206 PMID: 39607833", "39607833" ], [ "Anum Babar, Maham Babar, Hina Zubair, Arzu Shahid, Sana Rafique, Maimona Bano, Madeeha Subhan Waleed, Maimoona Khan, Arslan Inayat, Danish Safi (2024). Selinexor for the treatment of patients with relapsed or refractory multiple myeloma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 535-546. https://doi.org/10.1177/10781552241235902 PMID: 38454813", "38454813" ], [ "Huixing Zhou, Yafei Wang, Jiao Chen, Aili He, Jie Jin, Quanyi Lu, Ying Zhao, Junjun Li, Ming Hou, Liping Su, Xun Lai, Wei Wang, Lihong Liu, Yanping Ma, Da Gao, Wenhong Lai, Xin Zhou, Hongmei Jing, Jinqiao Zhang, Wei Yang, Xuehong Ran, Congmeng Lin, Jianping Hao, Taiwu Xiao, Zhenqian Huang, Zhigang Zhu, Qing Wang, Baijun Fang, Binghua Wang, Yanping Song, Zhen Cai, Bo Liu, Yanan Zhu, Xinai Yang, Xiaoyan Kang, Juan Li, Wenming Chen (2024). Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial. Annals of hematology, 855-868. https://doi.org/10.1007/s00277-023-05558-y PMID: 38112795", "38112795" ], [ "Andrew J Yee, Jacob P Laubach, Erica L Campagnaro, Brea C Lipe, Omar Nadeem, Robb S Friedman, Craig E Cole, Elizabeth O'Donnell, Giada Bianchi, Andrew R Branagan, Robert L Schlossman, Samantha J Shaprio, Cynthia C Harrington, Jill N Burke, Marilyn T Gammon, Kathleen J Lively, Cassandra A Reimonn, Danielle X Andrade, Robert A Redd, Jens G Lohr, Kenneth C Anderson, Paul G Richardson, Noopur Raje (2024). Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. Blood advances. https://doi.org/10.1182/bloodadvances.2024014717 PMID: 39626297", "39626297" ], [ "Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Donna Reece (2024). Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature medicine, 543-551. https://doi.org/10.1038/s41591-023-02703-y PMID: 38177852", "38177852" ], [ "Nadine Abdallah, Shaji K Kumar (2024). New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma. Hematology/oncology clinics of North America, 511-532. https://doi.org/10.1016/j.hoc.2023.12.013 PMID: 38216384", "38216384" ], [ "Jie Zhao, Hui Yang, Junnan Ge, Linyu Li, Qiong Yao, Shaolong He, Qiujuan Zhu, Ruiui Ren, Chunrui Li, Liangming Ma, Weiwei Tian, Jia Wei (2024). Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia/lymphoma with extramedullary disease. Blood science (Baltimore, Md.), e00184. https://doi.org/10.1097/BS9.0000000000000184 PMID: 38433987", "38433987" ], [ "Winfried Alsdorf, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Margherita Ursi (2024). Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of comparative effectiveness research, e240080. https://doi.org/10.57264/cer-2024-0080 PMID: 39162049", "39162049" ], [ "Ehsan Malek, Priyanka S Rana, Muthulekha Swamydas, Michael Daunov, Masaru Miyagi, Elena Murphy, James J Ignatz-Hoover, Leland Metheny, Seong Jin Kim, James J Driscoll (2024). The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial. Nature communications, 7388. https://doi.org/10.1038/s41467-024-51442-2 PMID: 39191755", "39191755" ] ] ], [ [ "Lenalidomide", "Diarrhea" ], 16.966773, [ [ "Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, Isabelle Fleury, Kamel Laribi, Juan-Miguel Bergua, Krimo Bouabdallah, Nicholas Forward, Fontanet Bijou, David MacDonald, Craig A Portell, Herve Ghesquieres, Grzegorz Nowakowski, Christopher A Yasenchak, Monica Patterson, Linda Ho, Evelyn Rustia, Michelle Fanale, Fei Jie, Jeong-A Kim (2025). Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2402242. https://doi.org/10.1200/JCO-24-02242 PMID: 39772655", "39772655" ], [ "Anna Furlan, Michele Cea, Laura Pavan, Monica Galli, Cristina Clissa, Silvia Mangiacavalli, Anna Maria Cafro, Stefania Girlanda, Francesca Patriarca, Claudia Minotto, Giovanni Bertoldero, Gregorio Barilà, Anna Pascarella, Albana Lico, Rossella Paolini, Nicholas Rabassi, Norbert Pescosta, Marika Porrazzo, Giovanni De Sabbata, Alessandra Pompa, Giulia Bega, Stefania Cavallin, Francesca Guidotti, Magda Marcatti, Maurizio Rupolo, Angelo Belotti, Filippo Gherlinzoni, Renato Zambello (2024). A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience. Cancer medicine, e7071. https://doi.org/10.1002/cam4.7071 PMID: 38558233", "38558233" ], [ "Giulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, Michelle Okwali, Irem Isgor, Philip C Caron, Zachary Epstein-Peterson, Paola Ghione, Paul Hamlin, Jennifer Lue, Steven M Horwitz, Andrew M Intlekofer, William Johnson, Anita Kumar, Alison Moskowitz, Ariela Noy, Colette Owens, Lia M Palomba, Pallawi Torka, Pallavi Galera, Andrew D Zelenetz, Gilles Salles, Lorenzo Falchi (2024). Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience. Haematologica. https://doi.org/10.3324/haematol.2024.285600 PMID: 39234863", "39234863" ], [ "Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Ioannis V Kostopoulos, Rodanthi-Eleni Syrigou, Evangelos Eleutherakis-Papaiakovou, Stavros Gkolfinopoulos, Ourania E Tsitsilonis, Efstathios Kastritis, Meletios A Dimopoulos (2024). Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study. Haematologica, 2594-2605. https://doi.org/10.3324/haematol.2023.284347 PMID: 38356458", "38356458" ], [ "Malin Hultcrantz, Hani Hassoun, Neha Korde, Kylee MacLachlan, Sham Mailankody, Dhwani Patel, Urvi A Shah, Carlyn Rose Tan, David J Chung, Oscar B Lahoud, Heather J Landau, Michael Scordo, Gunjan L Shah, Sergio A Giralt, Matthew J Pianko, Miranda Burge, Kelly Barnett, Meghan Salcedo, Julia Caple, Linh Tran, Jenna Blaslov, Tala Shekarkhand, Selena Hamid, David Nemirovsky, Andriy Derkach, Oluwatobi Arisa, Cody J Peer, William D Figg, Saad Z Usmani, Ola Landgren, Alexander M Lesokhin (2024). Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma. Blood cancer journal, 164. https://doi.org/10.1038/s41408-024-01136-1 PMID: 39300066", "39300066" ], [ "Malin Hultcrantz, Hani Hassoun, Neha Korde, Kylee Maclachlan, Sham Mailankody, Dhwani Patel, Urvi Shah, Carlyn Rose Tan, David J Chung, Oscar Lahoud, Heather Landau, Michael Scordo, Gunjan L Shah, Sergio Giralt, Matthew J Pianko, Miranda Burge, Kelly Barnett, Meghan Salcedo, Julia Caple, Linh Tran, Jenna Blaslov, Tala Shekarkhand, Selena Hamid, David Nemikovski, Andriy Derkach, Oluwatobi Arisa, Cody J Peer, William D Figg, Saad Z Usmani, Ola Landgren, Alexander M Lesokhin (2024). Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma. Research square. https://doi.org/10.21203/rs.3.rs-4406606/v1 PMID: 38883739", "38883739" ], [ "Michel Delforge, Krina Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S Marshall, Bertrand Arnulf, Michele Cavo, Ajay Nooka, Salomon Manier, Natalie Callander, Sergio Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa McKiver, Mark Cook, Paula Rodríguez-Otero (2024). Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. The Lancet. Haematology, e216-e227. https://doi.org/10.1016/S2352-3026(24)00005-X PMID: 38423700", "38423700" ], [ "X Yang, C L Li, J Chen, F F Che, R Xiao, H Li, J Huang, T Jiang, H Q Yang, H Wang, X C Kuang, X B Huang (2024). [Retrospective clinical study on cryopreservation-free integrated autologous hematopoietic stem cell transplantation model for newly diagnosed multiple myeloma]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 488-494. https://doi.org/10.3760/cma.j.cn121090-20230929-00152 PMID: 38964924", "38964924" ], [ "Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J Bahlis, Saad Z Usmani, Neil Rabin, Robert Z Orlowski, Kenshi Suzuki, Torben Plesner, Sung-Soo Yoon, Dina Ben Yehuda, Paul G Richardson, Hartmut Goldschmidt, Donna Reece, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Philippe Moreau (2023). Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1590-1599. https://doi.org/10.1200/JCO.22.00940 PMID: 36599114", "36599114" ], [ "Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M Ardeshna, Roderick Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam, Luis Fayad, John Radford, Sarah Bailly, Fritz Offner, David Morgan, Javier Munoz, Jerry Ping, Edith Szafer-Glusman, Karl Eckert, Jutta K Neuenburg, Andre Goy (2023). The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study. EClinicalMedicine, 101779. https://doi.org/10.1016/j.eclinm.2022.101779 PMID: 36618900", "36618900" ] ] ] ] }